极T代谢磁共振全球科研集锦
95
10 of 17 LARSON ET AL.
FIGURE 6 Sensitivity of metabolic rate estimates when using the fitting with input method, evaluating the response to fixing versus fitting the
bolus parameters
These results show that all approaches reduced the sensitivity of kPL estimates to errors in the bolus characteristics. Fitting the arrival time while
fixing the bolus duration, while introducing some increased bias with errors in bolus duration, provided an improvement in the expected variability.
As expected, fitting the bolus duration while fixing the arrival time introduced increased bias with errors in arrival time, but provided a further
improvement in the expected variability. Fitting both Tarrival and Tbolus reduced the sensitivity to Tbolus and Tarrival variations. Interestingly, fitting both
parameters also had little to no penalty on the expected kPL variance across most parameters and performed comparably to fitting only one of these
parameters. There was some bias when fitting both parameters, which was largest with a low SNR (휎 = .01) of −5%, although it was relatively small
in most cases.
3.1.5 kPL fitting for other flip-angle strategies
We have also applied the simulation framework for evaluating various analysis methods to other flip-angle strategies, presented in the Supporting
Information. The strategies presented there include a constant 10◦ for all time and metabolites, as well as a “multiband” 10◦ (pyruvate)–20◦ (lactate)
strategy that has been used in several prostate1 and brain5 human HP pyruvate exams.
When using fixed T1L and bolus characteristics, the inputless kPL fitting and calibrated AUCratio behave very similarly across both of the
constant-in-time flip-angle strategies shown: neither suffers from bias with variations in bolus characteristics or T1P. The inputless method has
极T代谢磁共振全球科研集锦
96
LARSON ET AL. 11 of 17
FIGURE 7 Sample in vivo maps of the metabolic AUCs as well as all fit parameters. T2 prostate lesions are highlighted by the green arrows in the
T2-weighted anatomical reference images. The tSNR and kPL maps are windowed independently for each subject. The three kPL maps are
windowed identically within each subject. All time values (mean time pyr, T1L, Tarrival and Tbolus) are in s and are windowed identically between
subjects. Fit parameters were only computed and shown where tSNRpyruvate > 80 in order to provide reliable fits
极T代谢磁共振全球科研集锦
97
12 of 17 LARSON ET AL.
improved precision slightly. Fitting with input suffers from bias with variations in bolus characteristics or T1P. All methods have bias with variations
in T1L and errors in the RF transmit power.
3.2 Human studies
Based on the simulation results described above, we chose to apply the calibrated AUCratio, inputless kPL fitting using a fixed T1L, inputless kPL fitting
including T1L fitting, and fitting with input using fixed T1L but fitting Tarrival and Tbolus to the human prostate datasets.
Sample parameter maps across a range of patients are shown in Figure 7. In general, there is a strong spatial agreement between the AUCratio and
kPL from inputless fitting, both with fitting and with fixed T1L, which also showed good correspondence with T2 lesions. Mean pyruvate time maps
indicate some variability in pyruvate arrival across the prostate. However, there are noticeable disagreements between the inputless kPL fitting
results (labeled kPL,fixed-T1L and kPL,fit-T1L) and the fitting including bolus input characteristics, kPL,withinput. The maps for bolus arrival and duration, Tarrival
and Tbolus, also showed relatively high heterogeneity, suggesting that the fitting with input was unstable in the human data.
The results of the inputless kPL fitting are summarized in Figure 8. Notably, the relationship between the calibratedAUCratio and kPL is quite variable
across studies. A likely explanation for this difference is variability in pyruvate delivery time between subjects, which is expected from the simulation
results in Figure 4. These showed high sensitivity of the calibrated AUCratio to variations in Tarrival and Tbolus. The mean pyruvate time values support
this explanation, where studies with earlier mean pyruvate times have higher AUCratio versus kPL slope and vice versa.
The results of the inputless kPL fitting including T1L fitting are summarized in Figure 9. The relationship between the calibrated AUCratio and kPL
was also variable across studies with this fitting approach, similarly to Figure 8. The T1L fitting in the prostate had average values within a subject
between 20 and 30 s and a standard deviation of around 10 s in most subjects. This highlights the relative instability of this fitting, which is somewhat
expected based on high variability in the simulation results when fitting T1L (Figure 5). Note that T1L was constrained during fitting to be between
15 and 35 s in an attempt to introduce some stability to these measurements. In the majority of voxels, the fitting hit these limits, as demonstrated
by a standard deviation of around 10 s in most subjects.
FIGURE 8 Summary of in vivo quantifications using the inputless kPL fitting with fixed T1L, where each color represents a different study. (a)
Comparison of the calibrated AUCratio and kPL values from inputless fitting with a fixed T1L across all prostate voxels. Eight representative studies
are shown for clear visualization. Linear fits between these parameters are shown as dashed lines. (b) Normalized histograms of the mean
pyruvate time (T휇,pyr in Equation (13)) for the same subjects as in (a), to provide a measure of pyruvate delivery time variations. (c) Comparison of
the linear fitting between the calibrated AUCratio and kPL versus the average T휇,pyr, for all 17 studies
极T代谢磁共振全球科研集锦
98
LARSON ET AL. 13 of 17
FIGURE 9 Summary of in vivo quantifications using inputless kPL fitting, with fitting T1L. (a) Comparison of the calibrated AUCratio and kPL values
across all prostate voxels for the same eight representative studies as in Figure 8. Linear fits between these parameters are shown as dashed lines.
(b) Mean and standard deviation of fit T1L values in the prostate from voxels with lactate tSNRlac > 20
FIGURE 10 Summary of in vivo quantifications using kPL fitting with input and a fixed T1L. (a) Comparison of the calibrated AUCratio and kPL values
across all prostate voxels for the same eight representative studies as in Figures 8 and 9. Linear fits between these parameters are shown as
dashed lines. (b) Comparison of the Tbolus and Tarrival fits in the prostate across all studies, showing mean and standard deviation of both
parameters. (c) Comparison of average Tbolus and Tarrival fits with the average T휇,pyr in the prostate across all studies
极T代谢磁共振全球科研集锦
99
14 of 17 LARSON ET AL.
TABLE 2 Summary of analysis results in the prostate across all patient studies. The fit parameter values shown are based only
on prostate voxel data. kPL values shown used the input-less fitting with fixed T1L
Polarization Pyr conc. Mean pyr Max Pyr Max Lac Max kPL mean kPL mean mean mean
ID (%) (mM) time (s) tSNR tSNR (1/s) (1/s) T1L (s) Tarrival (s) Tbolus (s)
1 36.2 245 29.4 864.3 185.9 0.024 0.009 25.7 5.7 8.4
2 37.3 235 24.8 314.4 85.0 0.014 0.010 18.3 0.0 6.0
3 47.9 250 28.0 303.1 49.5 0.021 0.008 28.1 1.6 7.0
4 45.4 226 29.8 897.1 52.0 0.009 0.003 27.2 4.9 8.5
5 47 251 32.3 297.8 59.3 0.017 0.007 18.8 9.7 9.8
6 36.7 227 27.8 249.1 69.1 0.033 0.011 28.7 1.7 6.9
7 38.2 221 28.7 1415.0 136.4 0.025 0.009 25.0 3.5 8.6
8 40.9 249 27.5 1257.5 161.4 0.018 0.007 29.1 0.8 6.5
9 39.8 246 29.7 786.7 67.7 0.019 0.006 27.0 3.7 8.6
10 36.3 254 27.0 424.9 111.6 0.019 0.011 21.5 0.0 6.5
11 36.9 244 31.1 1008.5 66.3 0.021 0.007 21.8 7.8 9.5
12 39.1 241 30.6 509.5 61.2 0.024 0.008 20.1 4.7 9.2
13 38.1 225 29.7 859.4 120.2 0.014 0.007 24.4 3.8 8.4
14 38.5 246 29.1 189.2 141.4 0.049 0.018 27.4 3.0 8.1
15 29.8 251 29.5 334.0 62.5 0.023 0.007 28.7 5.3 7.7
16 42 235 28.0 703.5 195.5 0.024 0.011 27.6 1.1 6.7
17 43.6 244 30.0 276.3 64.4 0.030 0.008 26.8 4.5 8.5
Mean 39.6 241 29.0 628.8 99.4 0.023 0.009 25.1 3.6 7.9
Std Dev 4.5 10 1.7 378.1 48.7 0.009 0.003 3.6 2.7 1.1
The results of the kPL fitting with input and fixed T1L are summarized in Figure 10. The relationship between the calibrated AUCratio and kPL was
also variable across studies with this fitting approach, but with more spread of kPL values compared with the inputless fitting results in Figures 8
and 9. This suggests more instability in the fitting with input. The input fit parameters Tarrival and Tbolus were correlated with each other (R2 = 0.836)
and also with the mean pyruvate time metric (R2 = 0.841 between mean pyruvate time and Tarrival, R2 = 0.882 between mean pyruvate time and
Tbolus). Both metrics showed notable intersubject variability in bolus delivery characteristics. There was substantial variation in Tarrival and Tbolus in
the majority of subjects, suggesting relatively unstable fitting, because presumably the bolus delivery would be relatively similar within the prostate.
Note that Tarrival and Tbolus were constrained during fitting to 0–12 s and 6–10 s, respectively, in an attempt to introduce some stability to these
measurements.
Table 2 summarizes the experimental characteristics and fitting values in the prostate across all patients studied. Much like prostate cancer itself,
there is a heterogeneous range of SNR, delivery, and kPL across this group.
4 DISCUSSION
In this work we evaluated approaches for quantification of metabolism in human HP [1-13C]pyruvate studies of prostate cancer patients and
presented normative ranges of experimental parameters, including metabolic conversion rates. We chose to apply three methods—a calibrated
AUCratio and kPL fitting with and without an input function—for quantification of pyruvate-to-lactate metabolic conversion. Part of the motivation for
these methods was their simplicity, which we expected to translate into robustness for low SNR data. These were chosen from amongst numerous
approaches for kinetic modeling of HP MRI data for their anticipated robustness to SNR and potential applicability to various flip-angle schemes.
The AUCratio method24 is extremely appealing in its simplicity of implementation. Under conditions of either constant-in-time flip angles acquired
starting prior to bolus arrival or consistent bolus characteristics, AUCratio is proportional to kPL divided by an effective lactate relaxation rate. This
proportionality breaks down when data acquisition starts after bolus arrival, and with variability in T1L that changes the effective lactate relaxation
rate. To accommodate the variable flip-angle scheme, we used a calibrated AUCratio for comparisons, which was calculated based on the nominal
bolus characteristics and relaxation rates. However, our results showed that this calibrated AUCratio experiences strong variability when bolus characteristics deviate from the assumed values. This was also evident from the analysis of our in vivo data, where the relationship between kPL and
AUCratio was highly variable across patients. Therefore, AUCratio is not suitable for quantifying metabolism in our prostate cancer experiments.
The lactate time-to-peak (TTP) was also recently introduced as a model-free approach for estimating metabolism.14 In this prior work, lactate
TTP performed indistinguishably from the best kinetic model in both in vitro and in vivo datasets. We performed simulations of this, as well as a
“mean lactate time” (shown in Supporting Information), and found that both of these lactate-only model-free approaches performed poorly for the
range of SNR and kPL values found in our human prostate cancer data with several flip-angle strategies. However, when we performed simulations
using higher SNRs and and higher kPL values, as was the case in Daniels et al,14 the TTP and mean lactate time performed comparably to the inputless
极T代谢磁共振全球科研集锦
100
LARSON ET AL. 15 of 17
kPL fitting with fixed T1L and AUCratio, with the mean lactate time performing better than TTP with our variable flip-angle scheme. Based on these
simulations, we believe these metrics are not valuable given the typical SNR and kPL values observed in our prostate cancer experiments.
Fitting of metabolic rates is often performed with either known input function or fitting of bolus characteristics, i.e. the input function
parameters.13,16,20,22 We evaluated this approach in simulations, first assuming a known input function.We found that the kPL fitting was highly sensitive to errors in the assumed input function. Using this approach is also challenging for our data, as we could not consistently identify a region for
estimation of an input function. It may also be more challenging to capture the bolus in our studies, due to the low pyruvate flip angles at the start of
the experiments. Adding some fitting of bolus characteristics reduced the sensitivity to errors in the input function, but substantially increased the
expected variance in the kPL estimates. In vivo fitting results also showed large variance in fit bolus characteristics and associated kPL maps. Therefore, we conclude that fitting including an input function was either too sensitive to errors or not precise enough to quantify metabolism in our
prostate cancer experiments.
The inputless kPL fitting method, inspired by Khegai et al,17 is appealing in that it requires no explicit input function, reducing the number of
parameters to fit. This fitting method only fits one or two parameters, depending on whether T1L is a free parameter. In our simulations, we found
that this approach had a similar precision to both the calibrated AUCratio and kPL fitting including an input function, but with the major advantage
that it was completely insensitive to the bolus characteristics. We included assumptions of fixing the relaxation rates, T1P and T1L, in this method.
Simulations showed that variations in T1P do not affect the fit results. However, the remaining limitation of this approach is sensitivity to variations
in T1L. While simulations indicated that fitting T1L would be an unfavorable trade-off due to the increased expected variance in kPL estimates, the in
vivo results did not show any obvious increases in kPL variance. Another advantage of the inputless approach is that it can be applied readily across
any acquisition strategy, i.e. for any flip angle or timing scheme. Therefore, we conclude that inputless kPL fitting was the most robust method for
quantifying metabolism in our prostate cancer experiments.
We found the major limitation of the inputless kPL fitting method to be sensitivity to T1L. In the model, kPL and T1L are competing effects of the same
order (0.01–0.1 /s), which may make separating these poorly conditioned.35 For example, increased generation of lactate via kPL combined with an
increased decay rate T1L would give somewhat similar dynamics to both rates being decreased. We chose our fixed T1L = 25 s based on modeling
values from our prior prostate cancer human studies1; this was also used by Bankson et al.13 Better estimates of in vivo metabolite relaxation rates
will improve the reliability of kinetic modeling. Another consideration for future work are recent studies suggesting that the intracellular T1 rates of
carboxylic acids, including pyruvate and lactate, may be much shorter than those in the extracellular environment, which were reported as being as
short as 10 s.36 This remains an important factor for this approach and likely many HP 13C kinetic modeling approaches, due to the poor conditioning
of these models.
Another limitation of all approaches for our experimental strategy was sensitivity to flip-angle errors. The simulation results show the inputless
approach is more sensitive to B1 errors compared with the fitting with input approach. One possible explanation is that the inputless fitting suffers
from increased error propagation in the pyruvate signal. B1 error will introduce consistent errors in the calculation of the pyruvate state magnetization, P−
Z [n], P+
Z [n], when it is computed directly from the actual pyruvate signal using the flip-angle compensations in Equations 4-7. The fitting
with input was less sensitive to B1 errors, possibly because the pyruvate magnetization is fitted in the model and not calculated directly from the
actual signal. We also suspect that some fitting methods include fit parameters that can end up compensating for B1 effects. For example, adding T1
fitting to the inputless method (Figure 5) reduces the B1 sensitivity overall. However, this is not strictly true, as when more parameters are added
to the fitting with input (Figure 6), the B1 effects are worse. The bias introduced by flip-angle errors can be eliminated through B1 mapping. Fast
Bloch–Siegert B1 mapping has been demonstrated for HP 13C,37-39 and more recently has been performed in real-time during the HP experiment40
to minimize bias due to inaccurate B1 calibration or unknown B1 field variations.
One potential improvement we did not explore that most certainly warrants future investigation is a tissue model that includes a vascular
compartment within each imaging voxel. This has been recently investigated by Bankson et al,13 and was shown to be a more appropriate tissue
model, as evaluated by the Akaike Information Criteria in preclinical study data. Similarly to this article, their work also assumed a unidirectional
pyruvate-to-lactate model with fixed relaxation rates. They also used a measured vascular input function (VIF) based on pyruvate signal in the heart,
as well as assumed known blood volume fractions from dynamic contrast-enhanced (DCE) MRI and pyruvate extravasation rates. This additional
information likely helps to maintain model stability when including a vascular compartment within each imaging voxel, which requires assumptions
or fitting of additional parameters. One reason we have not yet pursued this model is that we have not found a reliable way to estimate an input
function in our prostate cancer data, but this will be the subject of future work. It may be possible to estimate the input function across all voxels in
order to use a more complex tissue model.
The fitting methods and simulation evaluation framework can readily be extended to other applications beyond prostate cancer and other
metabolic pathways beyond pyruvate to lactate (e.g. pyruvate to bicarbonate and/or alanine), as well as other experimental parameters.We provide
guidance in the Supporting Information on modifying the simulations in the hyperpolarized-mri-toolbox.32 This framework could also be used for
retrospective design of experimental parameters, such as flip angles and TR, to obtain the best estimates of kPL for expected SNR, conversion rates,
relaxation rates, and bolus characteristics.
5 CONCLUSION
We have demonstrated the ability of MRI with hyperpolarized carbon-13 pyruvate to provide quantitative assessments of prostate cancer
metabolism using dynamic imaging and kinetic modeling, and presented normative ranges of bolus delivery, SNR, and metabolic conversion rates in
极T代谢磁共振全球科研集锦
101
16 of 17 LARSON ET AL.
the prostate. This work is all based on dynamic imaging with kinetic modeling methods to provide estimates of metabolism that are independent of
the bolus delivery characteristics. The AUCratio method for quantification of metabolism is robust under conditions of constant-in-time flip angles
and when data are acquired starting before the bolus delivery, but is affected by variability in T1L. The inputless kPL fitting method was shown to
be relatively robust for low SNR data for all flip-angle schemes and bolus characteristics, but is also sensitive to variability in T1L. There were differences of over 10 s in bolus arrival measurements across studies and several fold differences in total SNR within the prostate, and this variability
must be accommodated by the acquisition and analysis methods used in future studies.
ACKNOWLEDGMENT
We thank Mary McPolin, Kimberly Okamoto, Dr Peter Shin and Dr Eugene Milshteyn for their assistance in performing the patient studies.
This work was supported by the National Institutes of Health [grant numbers R01EB017449, R01EB016741, R01CA183071, R01CA211150,
and P41EB013598], as well as receiving research support from GlaxoSmithKline and GE Healthcare.
ORCID
Peder E. Z. Larson http://orcid.org/0000-0003-4183-3634
Hsin-Yu Chen http://orcid.org/0000-0002-2765-1685
REFERENCES
1. Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci Transl Med.
2013;5:198ra108.
2. Granlund K, Vargas HA, Lyashchenko SK, et al. Metabolic dynamics of hyperpolarized [1-13C] pyruvate in human prostate cancer. In Proceedings of the
World Molecular Imaging Congress. Honolulu, Hawaii; 2015: 1714-15. https://doi.org/10.1007/s11307-016-0968-3
3. Cunningham CH, Lau JYC, Chen AP, et al. Hyperpolarized 13C metabolic MRI of the human heart—Novelty and significance: Initial experience. Circ Res.
2016;119:1177-1182.
4. Aggarwal R, Vigneron DB, Kurhanewicz J. Hyperpolarized 1-[13C]-pyruvate magnetic resonance imaging detects an early metabolic response to
androgen ablation therapy in prostate cancer. European Urol. 2017;72(6):1028-1029.
5. Park I, Larson PEZ, Gordon JW, et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain
metabolism in patient studies. Magn Reson Med. 2018;80:864-873.
6. Miloushev VZ, Granlund KL, Boltyanskiy R, et al. Metabolic imaging of the human brain with hyperpolarized 13C pyruvate demonstrates 13c lactate
production in brain tumor patients. Cancer Res. 2018;78(14):3755-3760.
7. Ardenkjaer-Larsen JH, Leach AM, Clarke N, Urbahn J, Anderson D, Skloss TW. Dynamic nuclear polarization polarizer for sterile use intent.NMR Biomed.
2011;24:927-932.
8. Golman K, Zandt Ri, LercheM, Pehrson R, Ardenkjaer-Larsen JH.Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor
diagnosis. Cancer Res. 2006;66:10855-10860.
9. Cunningham CH, Chen AP, Lustig M, et al. Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products. J Magn Reson.
2008;193:139-146.
10. Larson PEZ, Kerr AB, Chen AP, et al. Multiband excitation pulses for hyperpolarized 13c dynamic chemical-shift imaging. J Magn Reson. 2008;194:
121-7.
11. Albers MJ, Bok R, Chen AP, et al. Hyperpolarized 13c lactate, pyruvate, and alanine: Noninvasive biomarkers for prostate cancer detection and grading.
Cancer Res. 2008;68:8607-15.
12. Bahrami N, Swisher CL, Von Morze C, Vigneron DB, Larson PEZ. Kinetic and perfusion modeling of hyperpolarized (13)C pyruvate and urea in cancer
with arbitrary RF flip angles. Quant Imaging Med Surg. 2014;4:24-32.
13. Bankson JA, Walker CM, Ramirez MS, et al. Kinetic modeling and constrained reconstruction of hyperpolarized [1-13c]-pyruvate offers improved
metabolic imaging of tumors. Cancer Res. 2015;75:4708-17.
14. Daniels CJ, McLean MA, Schulte RF, et al. A comparison of quantitative methods for clinical imaging with hyperpolarized 13c-pyruvate. NMR Biomed.
2016;29:387-399.
15. Harrison C, Yang C, Jindal A, et al. Comparison of kinetic models for analysis of pyruvate-to-lactate exchange by hyperpolarized 13 C NMR.NMR Biomed.
2012;25:1286-94.
16. Kazan SM, Reynolds S, Kennerley A, et al. Kinetic modeling of hyperpolarized (13)C pyruvate metabolism in tumors using a measured arterial input
function. Magn Reson Med. 2013;70:943-53.
17. Khegai O, Schulte RF, Janich MA, et al. Apparent rate constant mapping using hyperpolarized [1-(13)C]pyruvate. NMR Biomed. 2014;27:1256-65.
18. Li LZ, Kadlececk S, Xu HN, et al. Ratiometric analysis in hyperpolarized NMR (I): Test of the two-site exchange model and the quantification of reaction
rate constants. NMR Biomed. 2013;26:1308-20.
19. Mariotti E, Orton MR, Eerbeek O, et al. Modeling non-linear kinetics of hyperpolarized [1-13c] pyruvate in the crystalloid-perfused rat heart. NMR
Biomed. 2016;29:377-386.
20. Sun C, Walker CM, Michel KA, Venkatesan AM, Lai SY, Bankson JA. Influence of parameter accuracy on pharmacokinetic analysis of hyperpolarized
pyruvate. Magn Reson Med. 2018;79:3239-3248.
21. Witney TH, Kettunen MI, Brindle KM. Kinetic modeling of hyperpolarized 13c label exchange between pyruvate and lactate in tumor cells. J Biol Chem.
2011;286:24572-24580.
极T代谢磁共振全球科研集锦
102
LARSON ET AL. 17 of 17
22. Zierhut ML, Yen YF, Chen AP, et al. Kinetic modeling of hyperpolarized 13c1-pyruvate metabolism in normal rats and TRAMP mice. J Magn Reson.
2010;202:85-92.
23. Xu T, Mayer D, Gu M, et al. Quantification of in vivo metabolic kinetics of hyperpolarized pyruvate in rat kidneys using dynamic 13c MRSI. NMR Biomed.
2011;24:997-1005.
24. Hill DK, OrtonMR, Mariotti E, et al. Model free approach to kinetic analysis of real-time hyperpolarized 13c magnetic resonance spectroscopy data. PLoS
One. 2013;e71996:8.
25. Larson PEZ, Hu S, LustigM, et al. Fast dynamic 3DMR spectroscopic imaging with compressed sensing andmultiband excitation pulses for hyperpolarized
13c studies. Magn Reson Med. 2011;65:610-9.
26. Zhao L, Mulkern R, Tseng CH, et al. Gradient-echo imaging considerations for hyperpolarized 129xe MR. J Magn Reson B. 1996;113:179-183.
27. Nagashima K. Optimum pulse flip angles for multi-scan acquisition of hyperpolarized NMR and MRI. J Magn Reson. 2008;190:183-188.
28. Xing Y, Reed GD, Pauly JM, Kerr AB, Larson PEZ. Optimal variable flip angle schemes for dynamic acquisition of exchanging hyperpolarized substrates.
J Magn Reson. 2013;234:75-81.
29. Larson P, Shang H. Spectral-Spatial-RF-Pulse-Design: Version 1.2; 2018.
30. Maidens J, Gordon JW, Arcak M, Larson PEZ. Optimizing flip angles for metabolic rate estimation in hyperpolarized carbon-13 MRI. IEEE Trans Med
Imaging. 2016;35:2403-2412.
31. Larson PEZ, Bok R, Kerr AB, et al. Investigation of tumor hyperpolarized [1-13c]-pyruvate dynamics using time-resolved multiband RF excitation
echo-planar MRSI. Magn Reson Med. 2010;63:582-591.
32. Larson PEZ, Kerr AB, Milshteyn E, Zhu X, Maidens J, Gordon JW. hyperpolarized-mri-toolbox: Version 1.2; 2018.
33. Tropp J, Calderon P, Vigneron DB. Systems, methods and apparatus for an endo-rectal receive-only probe. US Patent 7 945 308; 2011.
34. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: Present and future. Curr Opin Urol.
2008;18:71-7.
35. Swisher CL, Larson PEZ, Kruttwig K, et al. Quantitative measurement of cancer metabolism using stimulated echo hyperpolarized carbon-13 MRS. Magn
Reson Med. 2014;71:1-11.
36. Karlsson M, Jensen PR, Ardenkjær-Larsen JH, Lerche MH. Difference between extra- and intracellular T1 values of carboxylic acids affects the
quantitative analysis of cellular kinetics by hyperpolarized NMR. Angew Chem Int Ed. 2016;55:13567-13570.
37. Sacolick LI, Wiesinger F, Hancu I, Vogel MW. B1 mapping by Bloch–Siegert shift. Magn Reson Med. 2010;63:1315-22.
38. Schulte RF, Sacolick L, Deppe MH, et al. Transmit gain calibration for nonproton MR using the Bloch–Siegert shift. NMR Biomed. 2011;24:1068-72.
39. Lau AZ, Chen AP, Cunningham CH. Integrated Bloch–Siegert B1 mapping and multislice imaging of hyperpolarized 13C pyruvate and bicarbonate in the
heart. Magn Reson Med. 2012;67:62-71.
40. Tang S, Milshteyn E, Reed GD, et al. A regional bolus tracking and real-time B1 calibration method for hyperpolarized 13C MRI. Magn Reson Med. 2018.
In press. https://doi.org/10.1002/mrm.27391
SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.
How to cite this article: Larson PEZ, Chen H-Y, Gordon JW, et al. Investigation of analysis methods for hyperpolarized 13C-pyruvate
metabolic MRI in prostate cancer patients. NMR in Biomedicine. 2018;e3997. https://doi.org/10.1002/nbm.3997
极T代谢磁共振全球科研集锦
103
Characterization of serial hyperpolarized
13C metabolic imaging in patients with
glioma
研究背景
研究对象
研究过程
ג极ࣅ༐ 13 (HP-13C) MRI ᅃዖᆩᇀ༑֪స代谢ݥڦൔႠׯၟरຍLj߀ଣضҵኢ֪॔ă Ԩ研৯ኼሞኙথ
సୀዎଐ࣒ڦኁዐჄ HP-13C ׯၟڦᅃዂႠLjժඓۨᇑኟྔ࠵ፇኯ၎ԲLjୀթՎዐޏ٪ሞᅴ代谢ă
3 ఁॳኾᇼኁࢅ 5 ఁාႠঌዊୀ࣒ኁ
ۯༀג极ࣅ༐13(HP-13C)MRIᅙׯ้ํྺظ༑༹֪ా代谢ڦഽۇٴ
रຍă๑ᆩጆோڦᅏഗཚۯࡗༀࢃ极ࣅ)DNP)ຨ้ሺഽ13Cڦࢃ႑
ࡽLjHP-13Cׯ༵ၟࠃକॠ֪Քऻݴጱሞৢஞጀพڦࢫ代谢ገڦࣅీ
૰ă
ሞටసዐLjHP [1-13C] եཛྷ໗ཚࡗԇॾළ໗ྃൠா (LDH) ாٝገࣅྺ
[1-13C] ළ໗Ljཚࡗ၍૭༹եཛྷ໗ྃൠா (PDH) ࢅ༐໗᷿ா (CA) ாٝገ
ࣅ] ྺ13C] ༐໗ൠჸLjܸ༵ٗࠃᅃዖമ࿄ᆶڦ༑༛টࢅᄟࣅଡ
໗ࣅ০ݛڦ݆ă
६ᇀᅴҵኢ代谢ڦയ૰Ljঌዊୀ࣒ኁڦ HP-13C ׯၟ༬ኙႴ༬
՚ഽۙă
Ԩ研৯ڦణڦሞॳኾᇼኁࢅথหঢ়ঌዊୀዎଐ࣒ڦኁዐLj๑
ᆩۯ૰ბॺఇݛ݆ઠኙჄۯༀ HP-13C ׯၟăԲড NAWM ాڦ
࠵] 1-13C] եཛྷ໗代谢Ljժೠݥࠚጲᇼኁᇑ࣒ኁኮक़ڦՎࣅॠֱLjᅜ
तୀթՎాڦ代谢၎ܔᇀ NAWM ڦՎࣅă
极T代谢磁共振全球科研集锦
104
研究结果
结 论
应用方向
๑ᆩ۠ेሞ T2 े FLAIR ࢅᮕࢫ T1 ेၟฉڦ kPL ၂๖ݣพბۨᅭڦቛ้ׯڦၟă ࣒ኁ P5 ሞक़ᅴዊႠթՎ
ዐ၄ืڦߛ kPLLjᇑዜྷڦ T2L ၎ԲLjCEL ాࢅዜྷڦኵ߸ߛ) A)Ǘ ܸ࣒ኁ P2 ၂๖ሌืڦߛ kPLLjٗ CEL ၠᇺ
܋ჽฦڟ T2LLjසӣॱཀྵ (B) ๖ă ࣒ኁ P4 ዐݘ࠽ืڦߛ kPL ܔᆌᇀᅜ᪓༹ྺዐ႐ժჽฦፑ֨ܮᄾӣዊࢅೄዊ
DŽӣॱཀྵDžDŽCDžݥڦۇٴڦሺഽ T2Lă ሞዖ൧ူLjթՎ kPL ۼକݣพბቛă
หঢ়ঌዊୀ࣒ኁڦ HP-13C ဣଚຕۯڦ૰ბఇ႙၂๖Lj୲ຕ kPL-NAWM ࢅ kPB-NAWM ሞጻၠฉᅃዂLjᇑॳኾ
ᇼኁڦ୲ຕएԨ၎ຼăੇე࠶ิׯवԞ݃ڇຼੇࢭᇑ࠵୲ຕڦኝ༹ืߛᆶ࠲Ljኄీᆯᇀ [1-13C] եཛྷ
໗ཚࡗ BBB ڦྔา३ณዂă ሞदթቛ࣒ڦኁዐLjᮕሺഽݥࢅሺഽթՎڦ kPL ᄺืߛLjയሞںഽۙକᅃဣଚหঢ়
ঌዊୀჱ႙ڦᅴ代谢Ljժኧ HP-13C ׯၟڦၳᆩă
సҵࢅୀ
极T代谢磁共振全球科研集锦
105
Contents lists available at ScienceDirect
NeuroImage: Clinical
journal homepage: www.elsevier.com/locate/ynicl
Characterization of serial hyperpolarized 13C metabolic imaging in patients
with glioma
Adam W. Autrya, Jeremy W. Gordona, Hsin-Yu Chena, Marisa LaFontainea, Robert Boka,
Mark Van Criekingea, James B. Slatera, Lucas Carvajala, Javier E. Villanueva-Meyera,
Susan M. Changb
, Jennifer L. Clarkeb, Janine M. Lupoa, Duan Xua, Peder E.Z. Larsona,
Daniel B. Vignerona,c, Yan Lia,⁎
a Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, USA
b Department of Neurological Surgery, University of California San Francisco, San Francisco, USA
c Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, USA
ARTICLE INFO
Keywords:
Hyperpolarized
Carbon-13
Metabolism
Kinetics
Glioma
Bevacizumab
ABSTRACT
Background: Hyperpolarized carbon-13 (HP-13C) MRI is a non-invasive imaging technique for probing brain
metabolism, which may improve clinical cancer surveillance. This work aimed to characterize the consistency of
serial HP-13C imaging in patients undergoing treatment for brain tumors and determine whether there is evidence of aberrant metabolism in the tumor lesion compared to normal-appearing tissue.
Methods: Serial dynamic HP [1-13C]pyruvate MRI was performed on 3 healthy volunteers (6 total examinations)
and 5 patients (21 total examinations) with diffuse infiltrating glioma during their course of treatment, using a
frequency-selective echo-planar imaging (EPI) sequence. HP-13C imaging at routine clinical timepoints overlapped treatment, including radiotherapy (RT), temozolomide (TMZ) chemotherapy, and anti-angiogenic/investigational agents. Apparent rate constants for [1-13C]pyruvate conversion to [1-13C]lactate (kPL) and [13C]
bicarbonate (kPB) were simultaneously quantified based on an inputless kinetic model within normal-appearing
white matter (NAWM) and anatomic lesions defined from 1
H MRI. The inter/intra-subject consistency of kPLNAWM and kPB-NAWM was measured in terms of the coefficient of variation (CV).
Results: When excluding scans following anti-angiogenic therapy, patient values of kPL-NAWM and kPB-NAWM were
0.020 s−1 ± 23.8% and 0.0058 s−1 ± 27.7% (mean ± CV) across 17 HP-13C MRIs, with intra-patient serial
kPL-NAWM/kPB-NAWM CVs ranging 6.8–16.6%/10.6–40.7%. In 4/5 patients, these values (0.018 s−1 ± 13.4% and
0.0058 s−1 ± 24.4%; n = 13) were more similar to those from healthy volunteers (0.018 s−1 ± 5.0% and
0.0043 s−1 ± 12.6%; n = 6) (mean ± CV). The anti-angiogenic agent bevacizumab was associated with global
elevations in apparent rate constants, with maximum kPL-NAWM in 2 patients reaching 0.047 ± 0.001 and
0.047 ± 0.003 s−1 ( ± model error). In 3 patients with progressive disease, anatomic lesions showed elevated
kPL relative to kPL-NAWM of 0.024 ± 0.001 s−1 ( ± model error) in the absence of gadolinium enhancement, and
0.032 ± 0.008, 0.040 ± 0.003 and 0.041 ± 0.009 s−1 with gadolinium enhancement. The lesion kPB in
patients was reduced to unquantifiable values compared to kPB-NAWM.
Conclusion: Serial measures of HP [1-13C]pyruvate metabolism displayed consistency in the NAWM of healthy
volunteers and patients. Both kPL and kPB were globally elevated following bevacizumab treatment, while progressive disease demonstrated elevated kPL in gadolinium-enhancing and non-enhancing lesions. Larger prospective studies with homogeneous patient populations are planned to evaluate metabolic changes following
treatment.
https://doi.org/10.1016/j.nicl.2020.102323
Received 28 April 2020; Received in revised form 15 June 2020; Accepted 21 June 2020
Abbreviations: HP-13C, hyperpolarized carbon-13; DNP, dynamic nuclear polarization; RT, radiotherapy; TMZ, temozolomide; PDH, pyruvate dehydrogenase; LDH,
lactate dehydrogenase; CA, carbonic anhydrase ⁎ Corresponding author at: Department of Radiology and Biomedical Imaging, University of California San Francisco, 185 Berry Street, Ste. 350, San Francisco, CA
94107, USA.
E-mail address: yan.li@ucsf.edu (Y. Li).
1HXUR,PDJH&OLQLFDO
$YDLODEOHRQOLQH-XQH
7KH$XWKRUV3XEOLVKHGE\\(OVHYLHU,QF7KLVLVDQRSHQDFFHVVDUWLFOHXQGHUWKH&&%<1&1'OLFHQVH
KWWSFUHDWLYHFRPPRQVRUJOLFHQVHV%<1&1'
极
T代谢磁共振全球科研集锦
106
1. Introduction
Dynamic hyperpolarized carbon-13 (HP-13C) MRI has emerged as a
powerful technique for non-invasively probing in vivo metabolism in
real time. By utilizing specialized instrumentation to transiently enhance the signal of 13C nuclei via dynamic nuclear polarization (DNP),
HP-13C imaging provides the ability to detect metabolic conversion of
labeled molecules following their intravenous injection (ArdenkjaerLarsen et al., 2003).
Among the diverse applications of HP-13C imaging, interrogating
brain metabolism remains a principal investigational interest. After
demonstrating the feasibility of using HP [1-13C]pyruvate as a molecular probe in preclinical animal studies (Golman et al., 2006; Park
et al., 2014); early human trials importantly showed that this molecule
is safely and rapidly transported across the blood brain barrier (BBB)
over experimental timescales (Park et al., 2018; Miloushev et al., 2018).
In the human brain, HP [1-13C]pyruvate undergoes enzymatic conversion to [1-13C]lactate via cytosolic lactate dehydrogenase (LDH) and [
13C]bicarbonate via mitochondrial pyruvate dehydrogenase (PDH)
and carbonic anhydrase (CA), thus providing an unprecedented means
of probing glycolytic and oxidative phosphorylation pathways (Fig. 1)
(Lunt and Vander Heiden, 2011; Saraste, 1999). Recent studies in
healthy volunteers have reported on the regional variation of brain
metabolism, as well as patterns of metabolite production that are
conserved over a wide age range (Grist et al., 2019; Lee et al., 2020).
Given the potential for highlighting aberrant cancer metabolism,
particular emphasis has been placed on characterizing HP-13C imaging
in patients with gliomas (Park et al., 2018; Miloushev et al., 2018).
Diffuse infiltrating gliomas comprise a heterogeneous class of brain
tumors, which are graded according to malignancy using histopathologic and molecular criteria (Louis et al., 2016). While the most
common and aggressive form of this disease is grade IV glioblastoma
(GBM), patients who are initially diagnosed with grade II or III glioma
may undergo malignant transformation to higher grades (Chaichana
et al., 2010). In the case of GBM, standard-of-care treatment currently
includes maximal surgical resection, radiation therapy (RT) and concurrent temozolomide (TMZ) chemotherapy, followed by 6 months of
adjuvant TMZ (Stupp et al., 2005). Since the effects of standard and
adjuvant therapies can often mimic or even mask disease using routine
anatomic
1
H MRI, HP-13C imaging may assist in monitoring response to
treatment (Winter et al., 2019; Da Cruz et al., 2011).
The purpose of the current study was to characterize serial dynamic
HP-13C imaging using a kinetic modeling approach (Larson et al., 2018
)
in healthy volunteers and patients who received treatment for glioma.
Apparent [1-13C]pyruvate metabolism within NAWM was compared in
volunteers versus patients and evaluated for variation across examinations, while metabolism within tumor lesions was assessed for
alterations relative to NAWM.
2. Methods
2.1. 13C hardware and calibration
All experiments were performed on a clinical 3 T whole body
scanner (MR 750; GE Healthcare, Waukesha, WI) equipped with 32-
channel multi-nuclear imaging capability. Details of the 13C receiver
and transmit coil hardware are contained in Supplementary Fig. 1.
Transmit RF power (TG) was calibrated using a 13C FID sequence with a
non-slice selective 90
○ pulse (GE Healthcare) on a head-shaped
phantom containing unenriched ethylene glycol (HOCH
2CH2OH, anhydrous, 99.8%, Sigma Aldrich, St. Louis, MO), doped with 17 g/L
(0.29 M) NaCl to recapitulate physiological loading (Autry et al., 2019).
2.2. Subject population and treatment
Three healthy volunteers andfive patients previously diagnosed
with infiltrating glioma (WHO grades II-IV) were recruited to the IRBapproved study following informed consent at the University of
California, San Francisco (Table 1). While the treatments prior to
HP-13C imaging varied across the patients, all had undergone surgery
(5/5) and a few had received chemoradiotherapy (RT/TMZ) (2/5) as
shown in Table 1. Over the course of serial HP-13C imaging, some patients had additional surgery (2/5), RT/TMZ (1/5), adjuvant RT (3/5),
bevacizumab (2/5), and other therapies further detailed in Table 1.
Supplementary Fig. 2 depicts individual patient treatment timelines and
their intervals of HP-13C imaging.
2.3. Sample polarization and QC
Hyperpolarization of [1-13C]pyruvate was performed on a SPINlab
system (General Electric, Niskayuna, NY) designed for clinical applications (Park et al., 2018). In order to maintain an ISO 5 environment,
pharmacists utilized an isolator (Getinge Group, Getinge, France) and
clean bench laminarflow hood for preparing pharmacy kits. Pharmacy
kitsfilled with a mixture of 1.432 g [1-13C]pyruvic acid (MilliporeSigma, Miamisburg, OH) and 28 mg electron paramagnetic agent
(EPA) (AH111501; GE Healthcare, Oslo, Norway) were loaded into the
SPINlab and polarized for at least 2.5 h with 140 GHz microwave radiation at 5 T and 0.8 K. Following polarization, the pyruvate and trityl
radical solution was rapidly dissolved in sterile water and passed
through afilter under pressure to achieve a residual trityl concentration
of < 3μM. This solution was then collected in a receiver vessel, neutralized, and diluted with a sodium hydroxide tris(hydroxymethyl)
aminomethane/ethylenediaminetetraacetic acid buffer solution. An
integrated quality control (QC) system rapidly measured the resulting
pH, temperature, residual EPA concentration, volume, pyruvate concentration, and polarization level. Upon completing the QC analysis,
the sample underwent terminal sterilization in afilter (0.2 µm; ZenPure, Manassas, VA) before being collected in a MEDRAD syringe
(Bayer HealthCare, Pittsburgh, PA).
Acceptable compounding tolerances for pharmacist release of the
sample were: 1) polarization≥15%; 2) pyruvate concentration,
220–280 mM; 3) EPA concentration≤3.0μM; 4) pH, 5.0–9.0; 5)
temperature, 25–37
○C; 6) volume > 38 mL; and 7) bubble point test
on sterilizingfilter passed at 50 psi. The injected volume of HP [1-13C]
Fig. 1. HP [1-13C]pyruvate brain metabolism. Diagram of HP [1-13C]pyruvate metabolism in the brain, which is characterized by two primary pathways: enzymatic conversion of [1-13C]pyruvate to [1-13C]lactate via cytosolic
lactate dehydrogenase (LDH); and successive conversion of [1-13C]pyruvate to 13CO2 and [13C]bicarbonate via mitochondrial pyruvate dehydrogenase (PDH)
and carbonic anhydrase (CA), respectively. The second-order kinetics of pyruvate-to-bicarbonate conversion are approximated by the rate-limiting step of
PDH, given the rapid CO
2-bicarbonate exchange catalyzed by CA. HP [1-13C]
pyruvate is also reversibly converted to [1-13C]alanine via alanine transaminase
(ALT), but prior studies have shown that conversion to HP [1-13C]alanine occurs outside of the brain (4).
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
107
pyruvate was based on a 0.43 mL/kg dosage, delivered at a rate of
5 mL/s, and followed by a 20 mL sterile salineflush at the same rate.
Supplementary Table 1 contains the experimental QC and injection
parameters, summarized as follows by the mean and range of values:
polarization, 41% (36–51%); pyruvate concentration, 238 mM
(216–255 mM); EPA concentration, 1.1μM (0.3–2.4μM); pH, 7.5
(6.1–8.3); temperature, 32
○C (29
–36
○C); volume, 29 mL (20
–40 mL);
time-to-injection, 58 s (49–83 s).
2.4. Serial imaging protocol
After confirming that patient vital signs permitted administration of
HP contrast, an intravenous catheter was placed in the antecubital vein. T2-weighted fast spin echo (FSE) images (TR/TE = 4000/60 ms,
FOV = 26 cm, 192× 256 matrix, 5 mm slice thickness, and NEX = 2)
acquired with the
1
H body coil or dual-tuned 13C/
1
H hardware configuration served as an anatomic reference for prescribing 13C sequences. An embedded 1 mL 8 M 13C-urea sample in the receiver array
provided in vivo frequency referencing for [1-13C]pyruvate: fpyruvate = furea + 270 Hz. Following pharmacist approval of sample
safety, patients were injected with the HP [1-13C]pyruvate and dynamic
HP-13C echo-planar imaging (EPI) data were acquired beginning 5 s
after the end of the salineflush to allow for cerebral bolus arrival.
A frequency-selective 2D multislice EPI sequence (TR/
TE = 62.5 ms/21.7 ms, 24× 24 cm
2 FOV, 1032 µs echospacing, ± 10 kHz BW, 8 slices, 20 timepoints, 3 s temporal resolution,
60 s total acquisition time) with 2–8 cm
3 spatial resolution (3.38 cm3
for 76% of scans) was acquired for each subject (Gordon et al., 2017;
Gordon et al., 2019). Individual [1-13C]pyruvate, [1-13C]lactate, and [
13C]bicarbonate resonances were sequentially excited using a singleband spectral-spatial (SPSP) RF pulse (130 Hz FWHM, 868 Hz stopband
peak-to-peak) over interleaved acquisitions with a variableflip angle
scheme that was constant through time (67% of scans utilized [αpyr
,
αlac,αbic] = [20
○, 30○, 30○]). The [1-13C]alanine resonance was not
acquired as prior studies have shown that it is only present in subcutaneous tissue and muscle outside the brain (Park et al., 2018).
Supplementary Table 2 contains the complete set of acquisition parameters for each EPI scan. Noise-only data were acquired separately
prior to each HP injection. To measure relative metabolite frequencies
for quality assurance, non-localized spectra (TR = 3 s,θ = 60
○, 8 time
points) were immediately acquired after thefirst scan with a 500μs
hard pulse.
After this scan, post-injection vital signs were measured and patients
received a routine
1
H MR examination using the same dual-tuned
hardware configuration (8-channel) or a 32-channel
1
H coil (Nova
Medical Inc., Wilmington, MA). This exam included pre- and post-gadolinium contrast 3D T1-weighted IRSPGR images (TR/TE/TI = 6636/
2468/450 ms, resolution = 1.5×1× 1 mm
3
, 25.6 cm FOV,
256× 256 matrix) and 3DT2-weighted FLAIR images (TR/TE/
TI = 6250/138/1702 ms, resolution = 1.5×1× 1 mm
3
, 25.6 cm
FOV, 256× 256 matrix).
2.5. ROI segmentation
For each
1
H exam, white matter was segmented on the pre-contrast
T1-weighted images using the FSL FAST algorithm (Zhang et al., 2001),
and the FLAIRT2-hyperintense lesion (T2L) and post-gadolinium contrast-enhancing lesion (CEL) were manually segmented by a trained
researcher with 3D Slicer software (Menze et al., 2015). A normal-appearing white matter (NAWM) mask was generated by subtracting the
T2L from the segmented white matter. In cases where data was not
acquired with dual-tuned
1
H/13C hardware,
1
H images and ROIs were
aligned to the body coilT2-weighted FSE images acquired during the 13C exam using FSL FLIRT (Jenkinson and Smith, 2001). Individual 13C
data voxels were exclusively categorized as NAWM or T2L/CEL when at
least 30% of their volume contained the
1
Table 1Subject populationH ROIs. This was
. Subject demographics, clinical characterization, and lesion volume for healthy volunteers (HV) and patients (P). IDH, isocitrate dehydrogenase; GBM, glioblastoma; NA, not applicable; Sx, surgery;
CCNU, lomustine; RT, radiation therapy; TMZ, temozolomide.
Subject ID Diagnosis Prior disease status Age (yr),
Sex
No. serial scans (totaltimespan)
Prior treatment Treatment at the time of imaging T2L, CEL volume (cm3)
HV1 NA NA 41 M 1 NA NA NAHV2 NA NA 59 M 2 (30 min) NA NA NAHV3 NA NA 40F 3 (174 dy) NA NA NA
P1 IDH mutant anaplastic
oligodendroglioma
Recurrent 52 M 3 (578 dy) 2 Sx, RT/TMZ, TMZ, CCNU Sx, RT 8–16, < 1
P2 IDH mutant GBM Recurrent 30F 9 (512 dy) 3 Sx RT/TMZ, bevacizumab, pembrolizumab, CCNU,
carboplatin
17–124, < 1–6
P3 IDH mutant GBM Recurrent 42 M 3 (301 dy) 2 Sx, RT/TMZ, TMZ,
bevacizumab
Bevacizumab 27–47, 6–12
P4 IDH mutant oligodendroglioma Non-Recurrent 49F 2 (224 dy) Sx None 44–87, 0P5 IDH wildtype GBM Recurrent 55F 4 (225 dy) Sx, RT/TMZ, veliparib/placebo Sx, RT pembrolizumab 26–175, 2–12
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
108
accomplished by subtracting the designated 13C voxels of the lesion
(T2L/CEL) from those of the NAWM.
2.6. Post-processing of 13C data
Raw dynamic EPI data were routinely processed by first determining the phase coefficients for removing ghosting artifacts (Wang
et al., 2017). Noise decorrelation via Cholesky decomposition was
employed to improve channel decoupling and the signal-to-noise ratio
(SNR) prior to EPI reconstruction (Pruessmann et al., 2001). Coil
combination was performed using complex weights derived from the
pyruvate data (Zihan et al., 2019). The data were finally phased for
each metabolite to provide zero-mean Gaussian noise for model-based
fitting (Crane et al., 2020). Software used in this study are available
online via the “Hyperpolarized MRI Toolbox” on Github (Crane et al.,
2020).
2.7. Kinetic modeling
Apparent rate constants for pyruvate-to-lactate (kPL) and pyruvateto-bicarbonate (kPB) conversion were quantified using an “inputless”
model (Larson et al., 2018), which approximated first-order kinetics.
While accounting for differences in applied flip angles, this model simultaneously fit phased dynamic data from [1-13C]lactate and [13C]
bicarbonate signals that had been summed over NAWM and T2L/CEL
ROIs. Error in reported kPL and kPB values was estimated from nonlinear
least squares residuals of the associated fitting and thresholded above
25%. Dynamic EPI data were also fit in a voxel-wise fashion to generate
apparent rate constant maps for visualization, when the total SNR
was > 3 for each metabolite. Illustrative kPL and kPB maps from a patient with GBM are shown together with corresponding dynamic traces
and ROIs in Fig. 2.
2.8. Analysis
To evaluate the consistency of kPL-NAWM and kPB-NAWM values across
serial scans and subjects, the coefficients of variation (CVs; SD/mean)
were calculated and expressed as percentages. Rate constant values
were qualitatively compared between NAWM and T2L/CEL.
3. Results
3.1. Healthy volunteers
Fig. 3A presents example dynamic EPI kPL and kPB maps from a
healthy volunteer, which demonstrate the spatial variation of apparent
HP [1-13C]pyruvate metabolism. By comparison to the cortex, cuneus
and deep gray structures, white matter displayed relatively lower apparent conversion rates, as modeled by both kPL and kPB (Fig. 3A).
While coverage of the kPB map was limited by the SNR of [13C]bicarbonate deep within the brain, kPL and kPB values were seen to spatially trend together (Fig. 3A). The 3 healthy volunteers (1 female, 2
male) who ranged 40–59 years-of-age (Table 1) collectively showed
similar kinetic profiles within NAWM over a total of 6 scans: kPLNAWM = 0.018 s−1 ± 5.0% (0.016–0.018 s−1
) and kPBNAWM = 0.0043 s−1 ± 12.6% (0.0035–0.0049 s−1
) [mean ± CV
(range)] (Fig. 3B; Table 2). Despite differences in receiver hardware
over scan intervals ranging from 30 min to 107 days, healthy volunteers
HV2 and HV3 further demonstrated consistency in serial kPL and kPB
values (Fig. 3B; Table 2).
3.2. Serial patients
A total of 21 serial HP-13C imaging exams were performed on the 5
patients (3 female, 2 male) who ranged 30–55 years-of-age. Table 1
presents a summary of diagnosis, clinical features, and treatment
history for each patient. Infiltrating gliomas in this cohort spanned the
range of disease aggressiveness and represented diverse histopathology:
1 IDH-mutant grade II oligodendroglioma; 1 IDH-mutant anaplastic
oligodendroglioma; and 3 grade IV GBM (2 IDH-mutant/1 IDH-wildtype) (Table 1) (Yan et al., 2019). Over the course of imaging, 3 patients
received RT and/or TMZ and 2 patients received the anti-angiogenic
agent bevacizumab as part of their treatment.
Table 2 provides a summary overview of the serial HP-13C kinetic
data for each patient, as quantified within the NAWM, T2L, and CEL,
together with the associated serial CVs. When excluding scans that
overlapped anti-angiogenic therapy, the mean kPL-NAWM and kPB-NAWM
over the remaining 17 of 21 scans were 0.020 s−1 ± 23.8%
(0.015–0.029 s−1
) and 0.0058 s−1 ± 27.7% (0.0037–0.0078 s−1)
[mean ± CV(range)], and intra-patient serial kPL-NAWM/kPB-NAWM demonstrated consistency with CVs ranging 6.8–16.6%/10.6–40.7%
(Table 2). In particular, for patients P1-4, values of kPLNAWM = 0.018 s−1 ± 13.4% (0.015–0.022 s−1
) and kPBNAWM = 0.0058 s−1 ± 24.4% (0.0037–0.0078 s−1
) [n = 13;
mean ± CV(range)] were more similar to those of healthy volunteers,
while patient P5 displayed consistently higher kPLNAWM = 0.028 s−1 ± 7.1% (mean ± CV) over 4 scans spanning
225 days (Table 2). When the acquired spatial resolution was 1.5 cm
isotropic or lower and the flip angle scheme was maintained over serial
imaging, kPL-NAWM and kPB-NAWM CVs were as low as 6.8% and 10.8%,
respectively, for 6 scans (patient P2).
In the two patients with limited to no treatment during imaging (P4
and P1), the mean apparent rate constants in NAWM were comparable
to that of healthy volunteers. Patient P4, who only received surgical
treatment prior to serial HP-13C imaging, showed kPLNAWM = 0.017 s−1 ± 16.6% and kPB-NAWM = 0.0045 s−1 ± 25.1%
(mean ± CV) over 2 scans spanning 224 days. Despite focal RT and
surgery between the second and last timepoints, patient P1 also demonstrated similar values of kPL-NAWM = 0.017 s−1 ± 7.3% and kPBNAWM = 0.0053 s−1 ± 34.0% (mean ± CV), which were consistent
over 3 scans spanning 525 days.
3.3. Effects of radiation and chemotherapy (TMZ)
In the 3 patients who received RT and/or TMZ during serial imaging
as part of treatment, values of kPL-NAWM were comparable across scans.
With adjuvant RT, patients P1 and P5 showed pre/post-radiotherapy
kPL-NAWM = 0.016 ± 0.001/0.016 ± 0.001 s−1 and 0.028 ± 0.001/
0.025 ± 0.002 s−1 ( ± error), with the last scans being 39 and 33 days
after RT, respectively. For two separate RT + TMZ treatments, patient
P2 showed pre/post-chemoradiotherapy kPL-NAWM = 0.021 ± 0.001/
0.020 ± 0.001 s−1 and 0.019 ± 0.001/0.022 ± 0.001 s−1
( ± error), with the last scans being 78 and 15 days after therapy, respectively.
3.4. Effects of anti-angiogenic therapy
Patient P2 presented an interesting case study on the effects of
treatment and the associated evolution of kinetic profiles within presumed tumor regions. In Fig. 4A, the kPL-NAWM, kPL-T2L and kPL-CEL are
shown together as colored traces for each of 9 scans that spanned
512 days, alongside a treatment axis detailing clinical management.
Over the first 6 exams, the kPL-NAWM indicated by the blue trace was
longitudinally consistent within 6.8% (CV), despite treatment with RT/
TMZ. However, kPL-T2L and kPL-CEL, shown as red and orange traces,
respectively, displayed elevations above kPL-NAWM and dynamic changes
during the same treatment interval. With the development of a new
enhancing lesion at the fifth timepoint (TP5) that persisted through the
next scan (TP6), there is a corresponding increase in kPL-T2L (8–11%)
and kPL-CEL (82–92%) above kPL-NAWM. Upon initiation of the anti-angiogenic agent bevacizumab, the enhancing lesion resolved at the seventh timepoint (TP7), while kPL increased globally. The elevation in
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
109
kPL-NAWM reached a maximum of 0.047 ± 0.001 s−1 ( ± error) at
62 days (TP8) after the first bevacizumab infusion, a 134% increase
over mean kPL-NAWM prior to treatment with bevacizumab. An analogous global increase in kPB-NAWM showed a maximum value of
0.011 ± 0.001 s−1 at the same time.
Fig. 4B shows the corresponding kPL maps overlaid on T1-weighted
images for timepoints 5–8, which demonstrated elevated kPL within the
new enhancing lesion and the drastic global change in kPL following
bevacizumab treatment. Approximately the same maximum value of
kPL-NAWM (0.047 ± 0.003 s−1
) was observed in patient P3 62 days
after bevacizumab treatment, representing a 198–234% elevation
above prior scans. Fig. 4C depicts the dynamic EPI traces for each
metabolite in NAWM from Fig. 4A,B before and after bevacizumab.
While the SNR was overall lower at the post-bevacizumab timepoint,
signal from both [1-13C]lactate and [13C]bicarbonate was proportionally higher relative to [1-13C]pyruvate.
3.5. Profiles of progression
Patients P2, P4, and P5 developed radiological progression over the
course of serial imaging, which was characterized by elevation of kPLT2L, and kPL-CEL in particular, relative to kPL-NAWM. Patient P2 exhibited
a mean ratio of kPL-CEL/kPL-NAWM = 1.77 from 3 to 6 cm3 of multi-focal
gadolinium-enhancing lesions, with individual lesion kPL-CEL ranging
from 0.032 ± 0.008 s−1 to 0.041 ± 0.009 s−1 ( ± error) over 3 scans
(Table 2). In the case of patient P5, the 12 cm3 pre-surgical enhancement showed a ratio of kPL-CEL/kPL-NAWM = 1.42 and kPLCEL = 0.040 ± 0.003 s−1 (Table 2). The mean ratio of kPL-T2L/kPLNAWM was 1.16 and 0.95 for patients P2 and P5, respectively (Table 2).
In contradistinction with other patients who progressed, patient P4
manifested an entirely non-enhancing lesion (87 cm2
) with kPL-T2L/kPLNAWM = 1.29 and kPL-T2L = 0.024 ± 0.001 s−1
. Progression timepoints for these patients are depicted in Fig. 5 with kPL maps overlaid on
T2-weighted FLAIR and post-gadolinium T1-weighted images. For patient P5, the kPL within the lesion was elevated relative to NAWM, and
also displayed spatial heterogeneity: the highest values were in and
Fig. 2. Example HP-13C kinetic maps. Regions of interest from a patient with GBM: NAWM (green) and T2L (red) overlaid on T1-weighted IRSPGR and T2-weighted
FLAIR images, respectively (A). Maps of kPL and kPB based on kinetic modeling of dynamic HP-13C EPI data overlaid on the same T1-weighted images (B, top).
Corresponding dynamic traces of HP [1-13C]pyruvate, [1-13C]lactate, and [13C]bicarbonate signal within NAWM are shown alongside kinetic model fits (B, bottom).
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
110
around the CEL, while the surrounding T2L kPL was comparatively
lower (Fig. 5A). Patient P2 likewise demonstrated an anatomical lesion
with elevated kPL that, in this example, extended beyond the CEL
margins into the non-enhancing T2L (Fig. 5B). The entirely non-enhancing T2L of patient P4 displayed corpus collosum involvement that
extended to the left frontal cortex and white matter, along with diffusely elevated kPL in the same region (Fig. 5C).
3.6. Quantifying lesion kPB
While kPL-T2L and kPL-CEL were quantifiable, estimates of lesion kPB
demonstrated errors exceeding 25% in all but one scan due to the low
13C bicarbonate signal within the T2L relative to NAWM.
Supplementary Fig. 3 illustrates the characteristically reduced metabolite signal in a radiologically stable T2L compared to the contralateral hemisphere for summed metabolite data with SNR > 3. These
data from patient P2 display less conversion of [1-13C]pyruvate to [13C]
bicarbonate within the T2L, but are below the noise floor and thus
cannot inform on the relative metabolic rate, kPB.
3.7. Evaluating exam quality
Analysis of the experimental parameters for patient P2, who demonstrated low CVs for kPL-NAWM (6.8%) and kPB-NAWM (10.6%) over 6
scans, provided a framework to evaluate exam quality. QC parameters
maintained for these 6 scan injections were: polarization > 33%, pyruvate concentration > 224 mM, and time-to-injection ≤55 s. Within
NAWM, the median total voxel SNR ranged 9.7–24.4 ([1-13C]lactate)
and 5.5–7.9 ([13C]bicarbonate) for 3.38–8 cm3 spatial resolution, and
allowed for rate constant errors of 2–6% (kPL-NAWM) and 7–9% (kPBNAWM). Because [13C]bicarbonate is the resolution-limiting metabolite,
it was determined that achieving a median voxel SNR ≥5.5 for [13C]
bicarbonate enabled ideal quantification error (kPB-NAWM error < 7%)
with the 1.5 cm isotropic resolution (3.38 cm3
).
Fig. 3. Volunteer HP-13C kinetic data. Maps of kPL and kPB from the third scan of healthy volunteer HV3 overlaid on T1-weighted images, which illustrate the spatial
variation of apparent HP [1-13C]pyruvate metabolism: 1, cortex/grey matter; 2, white matter; 3, cuneus; and 4, putamen/deep grey matter (A). Healthy volunteer
values of kPL-NAWM (B) and kPB-NAWM (C) are shown together with nonlinear least squares fitting error for 3 subjects over scan intervals of 30 min (a), 107 days (b) and
67 days (c).
Table 2
HP-13C kinetic data. Rate constants modeled from serial HP-13C data are shown for healthy volunteers (HV) and patients (P) within regions of interest.
SubjectID kPL-NAWM (s−1)
median (range)
kPL-T2L (s−1)
median (range)
kPL-CEL(s−1)
median (range)
kPB-NAWM (s−1)
median (range)
Mean kPL-T2L/kPL-NAWM Mean kPL-CEL/kPL-NAWM kPL-NAWM, kPB-NAWM CV (%)
HV1-3 0.018
(0.016–0.018)
NA NA 0.0043
(0.0035–0.0049)
NA NA 5.0, 12.6
P1 0.016
(0.016–0.018)
0.013
(0.013–0.013)
NA 0.0047
(0.0039–0.0074)
0.76 NA 7.3, 34.0
P2 0.021
(0.019–0.047)
0.025
(0.018–0.036)
0.035
(0.032–0.041)
0.0076
(0.0062–0.011)
1.16 1.77 6.8*, 10.6*
P3 0.016
(0.014–0.047)
0.021
(0.012–0.51)
0.018
(0.012–0.051
0.0064
(0.0042–0.0069)
1.09 1.01 8.0*, 29.4*
P4 0.017
(0.015–0.019)
0.022
(0.020–0.024)
NA 0.0045
(0.0037–0.0053)
1.30 NA 16.6, 25.1
P5 0.029
(0.025–0.029)
0.027
(0.021–0.031)
0.04 0.0059
(0.0033–0.0079)
0.95 1.42 7.1, 40.7
*CVs for 6 (P2) and 2 (P3) scans without bevacizumab treatment.
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
111
4. Discussion
This study characterized serial dynamic HP-13C imaging of the brain
in healthy volunteers and patients who underwent treatment for infiltrating glioma. Kinetic modeling of apparent [1-13C]pyruvate metabolism within NAWM demonstrated relatively consistent values of rate
constants across subjects over multiple exams and extended intervals.
While patients displayed longitudinal consistency in kPL-NAWM irrespective of various treatments, the initiation of anti-angiogenic therapy
coincided with the global elevation of rate constants. In cases of progressive disease, anatomic lesions showed elevated kPL relative to that
in the NAWM, which may reflect aberrant metabolism.
The consistency of NAWM kinetics in healthy volunteers is
noteworthy, given the importance of establishing an appropriate reference for defining pathological changes in [1-13C]pyruvate metabolism. These findings also agree with results from a prior study utilizing a
model-based spectroscopic imaging approach: the mean kPL-NAWM and
kPB-NAWM in 4 healthy subjects was 0.012 s−1 ± 6% and
0.002 s−1 ± 100% ( ± CV), respectively, compared to
0.018 s−1 ± 5.0% and 0.0043 s−1 ± 12.6% reported here (Grist
et al., 2019). While kinetic parameter values can vary according to the
echo time and signal weighting of the imaging sequence, the relative
ranges of kPL-NAWM in both studies provided evidence of inter-subject
consistency (Chen et al., 2019). Because [13C]bicarbonate detection
relies on the effective SNR that can be achieved within the experimental
framework, a variety of factors may have influenced the variability in
Fig. 4. Effects of bevacizumab. Serial kPL data within NAWM and presumed tumor regions are shown for patient P2 over 9 scans spanning 512 days, along with
clinical treatment information (A). Values of kPL-NAWM (blue) remained consistent until the administration of bevacizumab, whereupon a global increase in kPL
occurred, as seen at timepoint 8 (TP8) (A). Both kPL-T2L (red) and kPL-CEL (orange) are seen to be elevated relative to kPL-NAWM, particularly at the time of progression.
Corresponding kPL maps for timepoints TP5-TP8 overlaid on T1-weighted images illustrate the emergence of a new gadolinium-enhancing lesion with elevated kPL
(red arrows), which disappeared following treatment with bevacizumab, and subsequent global elevation of kPL (B). Kinetic traces from pre- and post-bevacizumab
scans demonstrate lower overall HP signal with bevacizumab, but proportionally greater [1-13C]lactate and [13C]bicarbonate signal relative to that of [1-13C]
pyruvate (C). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
112
quantification of kPB-NAWM from the prior study, including the use of a
single channel volume coil versus a multi-channel phased array.
Based on the kinetic modeling of apparent metabolism over the
course of serial HP-13C imaging, patients also demonstrated consistent
rate constants within NAWM. In the subject (P1) who received chemoradiotherapy prior to and RT during serial imaging, kPL-NAWM varied
only slightly between scans, with the mean value being similar to that
of healthy volunteers. Furthermore, interval changes in patient (P1, P2,
P5) kinetics following limited RT or TMZ were not apparent within a
routine 8 week window for clinical follow-up. These data, taken together with the overall consistency of kPL-NAWM observed in patients,
suggest that NAWM may be a suitable reference region against which to
compare alterations in [1-13C]pyruvate metabolism. This is promising
for potential applications geared toward monitoring response to
therapy, since standard 1
H MRI cannot adequately distinguish
treatment-induced changes from tumor (Winter et al., 2019; Da Cruz
et al., 2011).
Although serial scans generally demonstrated longitudinal consistency, anti-angiogenic therapy appeared to produce global alterations in the rates constants. For two patients, the most pronounced
increase in kPL and kPB followed an approximately 2-month interval
from the initiation of bevacizumab. As a monoclonal antibody designed
to normalize tumor vasculature through anti-VEGF activity, bevacizumab has become a tool for managing refractory brain edema and
salvage therapy (Cuncannon et al., 2019). Because of its effective reduction of blood–brain barrier (BBB) permeability, gadolinium-enhancing lesions, which are the radiological hallmark of GBM, can often
completely resolve, thus challenging clinical interpretations of tumor
progression (Villanueva-Meyer et al., 2017). With regard to HP-13C
imaging, the data suggest that [1-13C]pyruvate extravasation is reduced
Fig. 5. Profiles of progression. Imaging at the time
of radiologically-defined progression shown using kPL
maps overlaid on T2-weighted FLAIR and post-gadolinium T1-weighted images. Patient P5 demonstrated
elevated kPL in the lesion that was spatially heterogeneous, with higher values in and around the CEL
compared to the surrounding T2L (A); whereas patient P2 showed uniformly elevated kPL that extended
distally from the CEL into the T2L, as indicated by the
white arrow (B). Diffusely elevated kPL in patient P4
corresponded with a large non-enhancing T2L centered in the corpus callosum and extending to the left
frontal white matter and cortex (white arrows) (C). In
each case, the lesion kPL highlighted radiological
progression.
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
113
as a result of vascular changes induced by bevacizumab, which cause
conversion to downstream metabolites to appear more rapid by relative
proportions. This is a plausible mechanism, given that [1-13C]pyruvate
is much smaller than the gadolinium chelates utilized by contrast
agents, thereby allowing greater transport across the BBB under conditions of reduced permeability (Gerstner et al., 2019).
A critical finding in the three patients with progressive disease was
that anatomic lesions manifested elevated kPL compared to the surrounding NAWM. In each instance of gadolinium-enhancement, the
CEL showed a regional kPL maximum over the entire T2L, potentially
indicating aberrant metabolism associated with disease, i.e., the
Warburg effect and up-regulation of LDHA expression (Warburg, 1956;
Valvona et al., 2016). Although there is evidence of gadolinium deposition after contrast-enhanced MRI (McDonald et al., 2015), signal
loss due to potential deposition over serial exams is not a concern for
HP imaging because the relaxivity of commercial gadolinium-based
contrast agents is substantially lower on 13C than water (Gabellieri and
Leach, 2009; Smith et al., 2012). The heterogeneity of kPL observed
across the anatomic lesion in patient P5 may be reflective of the underlying features of GBM metabolism and the spatial extent of disease
within the T2L, which cannot be distinguished from vasogenic edema
on routine imaging. Such edema reduces normal perfusion (Bastin
et al., 2006) in a manner that appeared to lower [1-13C]pyruvate signal
and apparent conversion in this study, and thus requires careful evaluation. Patient P2 additionally demonstrated a non-enhancing T2-hyperintense lesion with elevated kPL-T2L during the initial progression,
which may have indicated infiltrative disease. Even the entirely nonenhancing lesion of patient P4 displayed diffuse elevation of kPL-T2L that
provided evidence of metabolic abnormality in low-grade disease.
These results were obtained in the challenging post-treatment context,
where lesions typically present with less volume and gadolinium-enhancement than newly diagnosed disease. Nonetheless, the findings
support the potential utility of HP-13C imaging in differentiating
treatment-induced changes from progressive enhancing or non-enhancing tumor.
While kPB was readily quantified in NAWM, estimates of lesion values were challenging owing to the lower [13C]bicarbonate signal. This
comparatively lower signal in the T2L at a voxel-wise level provided
evidence of less conversion from [1-13C]pyruvate and reduced TCA
cycle metabolism (Martinez-Reyes and Chandel, 2020), which is itself
an important observation concerning the influence of edema and tissue
environment. Whether certain gliomas display measurably reduced kPB
as part of a malignant metabolic phenotype remains to be determined.
Using the data from patient P2,who demonstrated low CVs over
serial scans, it was possible to provide experimental guidelines for
achieving adequate SNR. From a QC standpoint, maintaining a time-toinjection ≤55 s preserved enough hyperpolarization to obtain reliable
data at higher resolutions. Furthermore, the isotropic spatial resolution
of 1.5 cm (3.38 cm3
) demonstrated sufficient SNR (median voxel SNR
≥5.5 in NAWM) for quantification, based on the model fitting error for
[
13C]bicarbonate, which limits resolution. This resolution also represented a practical tradeoff with model error to maintain repeatability, and not necessarily an absolute limit.
In this study, a first-order, single compartment model was able to
consistently quantify kPL and kPB in high-quality datasets, however it is
worth noting the potential influence of certain biological factors. The
measured signals are a combination of vascular and intracellular/extracellular metabolite pools and depend on compartmentalized 13Clabel exchange (Bankson et al., 2015). Thus, highly perfused tumor can
appear to have lower rate constants by comparison to regions that
display normal perfusion when vascular [1-13C]pyruvate is not excluded. Additionally, there are a number of the factors influencing 13Clabel exchange via enzymatic conversion: while kPL has been shown to
correlate with LDH, pre-clinical studies have shown that values of kPL
can also be influenced by the pyruvate delivery rate, vascular/cellular
compartment permeability, monocarboxylate transporter (MCT)
expression/activity, metabolite pool sizes, LDH expression/activity,
associated cofactor nicotinomide adenine dinucleotide (NADH) levels,
and cellularity (Bankson et al., 2015; Hurd et al., 2010). Although
overexpression of MCT4 in GBM (Miranda-Goncalves et al., 2013) may
facilitate lactate efflux, the “pool size effect” of excess endogenous
lactate from LDH overexpression/hyperactivity likely promotes elevated kPL relative to healthy tissue (Day et al., 2007). Since this study
did not account for nonlinear enzyme reaction velocities described by
Michaelis-Menten kinetics under conditions of sufficiently high substrate concentration, deviations related to pyruvate saturation effects
were possible (Xu et al., 2011).
Further interrogating [1-13C]pyruvate metabolism in patients with
glioma will entail a variety of tactics that are aimed at improving both
analysis and methodology. From an analysis standpoint, the application
of the inputless kinetic model provided regionally consistent measures
of apparent rate constants. While proving largely robust to variations in
receiver hardware, it may have been affected by changes in the acquired spatial resolution and flip angle scheme over the developmental
phase of the study, owing to partial volume effects in the first case and
model limitations in the second. Most of the intra-subject variability
likely resulted from lower SNR in the data with higher than 1.5 cm
isotropic resolution or changing flip angle schemes between serial
scans. With a variable resolution (Gordon et al., 2018) acquisition
scheme, resolution could be defined independently for each metabolite
on the basis of SNR, thereby improving [13C]bicarbonate measurement
and kPB quantification. Being able to extend quantification with an
accounting of the vascular contributions of [1-13C]pyruvate, and to a
lesser extent [1-13C]lactate (Chaichana et al., 2010), will enhance the
ability to detect aberrant metabolism and potentially monitor response
to treatment. Because of the strong dependence on SNR for quantifying
HP data and resolving finer regions of metabolism, additional hardware
and reconstruction improvements will be critical to clinically translating this technology (Crane et al., 2020). Implementing atlas-based
prescription routines for HP acquisitions would also augment the ability
to compare data longitudinally on a voxel-wise basis (Bian et al., 2018).
Furthermore, by enrolling larger cohorts of patients with newly diagnosed disease and age-matched controls the range of population differences can be characterized along with metabolism associated with
disease.
5. Conclusion
Kinetic modeling of serial HP-13C data from patients with glioma
demonstrated consistent values of rate constants kPL-NAWM and kPBNAWM longitudinally, which were mostly similar to those of healthy
volunteers. The anti-angiogenic agent bevacizumab appeared to be
associated with a global elevation of apparent rate constants that may
have resulted from reduced extravasation of [1-13C]pyruvate through
the BBB. In patients with progressive disease, the kPL was also elevated
in both gadolinium-enhancing and non-enhancing lesions, potentially
highlighting aberrant metabolism across a range of glioma subtypes and
supporting the utility of HP-13C imaging.
CRediT authorship contribution statement
Adam W. Autry: Conceptualization, Methodology, Formal analysis,
Writing - original draft. Jeremy W. Gordon: Conceptualization,
Methodology, Writing - review & editing. Hsin-Yu Chen: Methodology,
Writing - review & editing. Marisa LaFontaine: Writing - review &
editing. Robert Bok: Writing - review & editing. Mark Van Criekinge:
Resources, Writing - review & editing. James B. Slater: Resources,
Writing - review & editing. Lucas Carvajal: Resources, Writing - review
& editing. Javier E. Villanueva-Meyer: Conceptualization, Writing -
review & editing. Susan M. Chang: Conceptualization, Funding acquisition, Writing - review & editing. Jennifer L. Clarke:
Conceptualization, Funding acquisition, Writing - review & editing.
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
114
Janine M. Lupo: Conceptualization, Funding acquisition, Writing -
review & editing. Duan Xu: Conceptualization, Writing - review &
editing. Peder E.Z. Larson: Conceptualization, Methodology, Writing -
review & editing. Daniel B. Vigneron: Conceptualization,
Methodology, Funding acquisition, Writing - review & editing. Yan Li:
Conceptualization, Supervision, Funding acquisition, Writing - review &
editing.
Acknowledgements
This work is dedicated to the late professor Sarah J Nelson, and was
supported by NIH Grants R01 CA127612, P01 CA118816, P41
EB0341598, P50 CA097257, and T32 CA151022, together with the
Glioblastoma Precision Medicine Program.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2020.102323.
References
Ardenkjaer-Larsen, J.H., Fridlund, B., Gram, A., et al., 2003. Increase in signal-to-noise
ratio of > 10,000 times in liquid-state NMR. PNAS 100, 10158–10163.
Autry, A.W., Gordon, J.W., Carvajal, L., Mareyam, H., Chen, H.Y., Park, I., Mammoli, D.,
Vareth, M., Chang, S.M., Wald, L.L., Xu, D., Vigneron, D.B., Nelson, S.J., Li, Y., 2019.
Comparison between 8- and 32-channel phased-array receive coils for in vivo hyperpolarized 13 C imaging of the human brain. Magn. Reson. Med. 82, 833–841.
Bankson, J.A., Walker, C.M., Ramirez, M.S., et al., 2015. Kinetic modeling and constrained reconstruction of hyperpolarized [1-13C]-pyruvate offers improved metabolic imaging of tumors. Cancer Res. 75 (22), 4708–4717.
Bastin, M.E., Carpenter, T.K., Armitage, P.A., Sinha, S., Wardlaw, J.M., Whittle, I.R.,
2006. Effects of dexamethasone on cerebral perfusion and water diffusion in patients
with high-grade glioma. AJNR 27 (2), 402–408.
Bian, W., Li, Y., Crane, J.C., Nelson, S.J.N., 2018. A fully automated atlas based method
for prescribing 3D PRESS MR spectroscopic imaging: towards robust and reproducible metabolite measurements in human brain. Magn. Reson. Med. 79 (2),
636–642.
Chaichana, K.L., McGirt, M.J., Laterra, J., Olivi, A., Quinnones-Hinojosa, A., 2010.
Recurrence and malignant degeneration after resection of adult hemispheric lowgrade gliomas. J. Neurosurg. 112 (1), 10–17.
Chen, H.Y., Gordon, J.W., Bok, R., Cao, P., et al., 2019. Pulse sequence considerations for
quantification of pyruvate-to-lactate conversion kPL in hyperpolarized 13C imaging.
NMR Biomed. 32 (2), e4052.
Crane, J.C., Gordon, J.W., Chen, H,Y., Autry, A.W., et al., 2020. Hyperpolarized 13C MRI
data acquisition and analysis in prostate and brain at University of California, San
Francisco. NMR Biomed. 2020; e4280.
Cuncannon, M., Wong, M., Jayamanne, D., Guo, L., Cove, N., Wheeler, H., Back, M., 2019.
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory
glioblastoma. BMC Cancer 445.
Da Cruz, L.C.H., Rodriguez, I., Domingues, R.C., Gasparetto, E.L., Sorensen, A.G., 2011.
Pseudoprogression and pseudoresponse: imaging challenges in the assessment of
posttreatment glioma. AJNR 32 (11), 1978–1985.
Day, S.E., Kettunen, M.I., Gallagher, F.A., et al., 2007. Detecting tumor response to
treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.
Nat. Med. 13, 1382–1387.
Gabellieri, C., Leach, M.O., Eykyn, 2009. Modulating the relaxivity of hyperpolarized
substrates with gadolinium contrast agents. Contrast Media Mol. Imaging 4, 143–147.
Gerstner, E., Emblem, K.E., Chang, K., et al., 2019. Bevacizumab reduces permeability
and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. Clin. Cancer Res. 26, 206–212.
Golman, K., Zandt, R.I., Lerche, M., Pehrson, R., Ardenkjaer-Larsen, J.H., 2006. Metabolic
imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 66, 10855–10860.
Gordon, J.W., Chen, H.Y., Autry, A., Park, I., Van Criekinge, M., Mammoli, D., et al.,
2019. Translation of carbon-13 EPI for hyperpolarized MR molecular imaging of
prostate and brain cancer patients. Magn. Reson. Med. 81, 2702–2709.
Gordon, J.W, Milshteyn, E., Vigneron Daniel, B., Larson Peder, E.Z., 2018. Variable
Resolution Echo-Planar Imaging for Improved Quantification of Hyperpolarized 13C
Metabolism. In Proceedings of the 26th Annual Meeting of ISMRM, Paris, France,
2018 (Abstract#3053).
Gordon, J.W., Vigneron, D.B., Larson, P., 2017. Development of a symmetric echo planar
imaging framework for clinical translation of rapid dynamic hyperpolarized 13C
imaging. Magn. Reson. Med. 77, 826–832.
Grist, J.T., McLean, M.A., Fiemer, F., Schulte, R.F., Deen, S.S., Zaccagna, F., et al., 2019.
Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate
and magnetic resonance imaging. NeuroImage 189, 171–179.
Hurd, R.E., Yen, Y.F., Tropp, J., et al., 2010. Cerebral dynamics and metabolism of hyperpolarized [1-(13)C]pyruvate using time-resolved MR spectroscopic imaging. J.
Cereb. Blood Flow Metab. 30 (10), 1734–1741.
Jenkinson, M., Smith, S.M., 2001. A global optimisation method for robust affine registration of brain images. Med. Image Anal. 5, 143–156.
Larson, P.E.Z., Chen, H.Y., Gordon, J.W., Korn, N., Maidens, J., Arcak, M., Tang, S.,
Criekinge, M., Carvajal, L., Mammoli, D., Bok, R., Aggarwal, R., Ferrone, M., Slater,
J.B., Nelson, S.J., Kurhanewicz, J., Vigneron, D.B., 2018. Investigation of analysis
methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients.
NMR Biomed. 31 (11), e3997.
Lee, C.Y., Soliman, H., Geraghty, B.J., Chen, A.P., Connelly, K.A., Endre, R., Perks, W.J.,
Heyn, C., Black, S.E., Cunningham, C.H., 2020. Lactate topography of the human
brain using hyperpolarized 13C-MRI. NeuroImage 204, 116202.
Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee,
W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., 2016. The 2016 World
Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 31 (6), 803–820. https://doi.org/10.1007/s00401-016-
1545-1.
Lunt, Y.L., Vander Heiden, M.G., 2011. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441–464.
Martinez-Reyes, I., Chandel, N.S., 2020. Mitochondrial TCA cycle metabolites control
physiology and disease. Nat. Commun. 11 (102).
McDonald, R.J., McDonald, J.S., Kallmess, D.F., et al., 2015. Intracranial gadolinium
deposition after contrast-enhanced MR imaging. Radiology 275 (3), 772–782.
Menze, B.H., Jakab, A., Bauer, S., Kalpathy-Cramer, J., Farahani, K., Kirby, J., et al., 2015.
The multimodal brain tumor image segmentation benchmark (BRATS). IEEE Trans.
Med. Imaging 34 (10), 1993–2024.
Miloushev, V.Z., Granlund, K.L., Boltyanskiy, R., et al., 2018. Metabolic imaging of the
human brain with hyperpolarized 13C pyruvate demonstrates 13C lactate production
in brain tumor patients. Cancer Res. 78, 3755–3760.
Miranda-Goncalves, V., Honavar, M., Pinheiro, C., et al., 2013. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro
Oncol. 15 (2), 172–188.
Park, I., Larson, P.E.Z., Tropp, L.T., et al., 2014. Dynamic hyperpolarized carbon-13 MR
metabolic imaging of nonhuman primate brain. Magn. Reson. Med. 71 (1), 19–25.
Park, I., Larson, P.E.Z., Gordon, J.W., et al., 2018. Development of methods and feasibility
of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in
patient studies. Magn. Reson. Med. 80, 864–873.
Pruessmann, K.P., Wieger, M., Boernert, P., Boesiger, P., 2001. Advances in sensitivity
encoding with arbitrary k-space trajectories. Magn. Reson. Med. 46, 638–651.
Saraste, M., 1999. Oxidative phosphorylation at the fin de siècle. Science 283 (5407),
1488–1493.
Smith, M.R., Peterson, E.T., Gordon, J.W., et al., 2012. In vivo imaging and spectroscopy
of dynamic metabolism using simultaneous 13C and 1
H MRI. IEEE Trans. Biomed.
Eng. 59 (1), 45–49.
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., et al.,
2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N. Engl. J. Med. 352 (10), 987–996.
Valvona, C.J., Fillmore, H.L., Nunn, P.B., Pilkington, G.J., 2016. The regulation and
function of lactate dehydrogenase A: therapeutic potential in brain tumor. Brain
Pathol. 26 (1), 3–17.
Villanueva-Meyer, J.E., Mabray, M.C., Cha, S., et al., 2017. Current clinical brain tumor
imaging. Neurosurgery 81 (3), 397–415.
Wang, J., Wright, A.J., Hesketh, R.L., Hu, D., Brindle, K.M., 2017. A referenceless Nyquist
ghost correction workflow for echo planar imaging of hyperpolarized [1-13C]pyruvate and [1-13C]lactate. NMR Biomed. 31 (2), e3866.
Warburg, O., 1956. On respiratory impairment in cancer cells. Science 124 (3215),
269–270.
Winter, S.F., Loebel, F., Loeffler, J., Batchelor, T.T., Martinez-Lage, M., Vajkoczy, P.,
Dietrich, J., 2019. Treatment-induced brain tissue necrosis: a clinical challenge in
neuro-oncology. Neuro Oncol. noz048.
Xu, T., Mayer, D., Gu, M., et al., 2011. Quantification of in vivo metabolite kinetics of
hyperpolarized pyruvate in rat kidneys using dynamic 13C MRSI. NMR Biomed. 24
(8), 997–1005.
Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., BatinicHaberle, I., Jones, S., Riggins, G.J., Friedman, H., Friedman, A., Reardon, D.,
Herndon, J., Kinzler, K.W., Velculescu, V.E., Vogelstein, B., Bigner, D.D., 2019. IDH1
and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773.
Zhang, Y., Brady, M., Smith, S., 2001. Segmentation of brain MR images through a hidden
random field model and the expectation maximization algorithm. IEEE Trans. Med.
Imaging 20, 45–57.
Zihan, Z., Zhu, X., Ohliger, M.A., Tang, S., Cao, P., Carvajal, L., et al., 2019. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human
studies. J. Magn. Reson. 301, 73–79.
A.W. Autry, et al. 1HXUR,PDJH&OLQLFDO
极T代谢磁共振全球科研集锦
115
Hyperpolarized 13C-pyruvate MRI detects
real-time metabolic flux in prostate cancer
metastases to bone and liver:
a clinical feasibility study
研究背景
研究对象
研究过程
ג极ࣅ) HP) 13C- եཛྷ໗ MRI ᅃዖ࿘ۨཞ࿋໎ݴጱׯၟఇ๕Lj༵ࠃ้ํೠࠚටૌമଚ၇ҵዐཚࡗ༛ট০ڦ代
谢୲ăങৃྺኹኄዖׯၟఇ๕ᅙںࠀׯᆩᇀമଚ၇ҵሞਆևदթዐăۅଣض研৯ֱۙକ HP 13C- եཛྷ໗ MR 代
谢ׯၟሞമଚ၇ҵገᅎ࣒ኁDŽሞࠡỞࢅాሤഄഗڦ࠳ገᅎDžዐڦႜႠׯࢅၟႠă
6 ఁ࣒ᆶገᅎႠඁڸੇႠമଚ၇ҵ࣒ڦኁ
ገᅎඁڸੇႠമଚ၇ҵDŽmCRPCDžፌዂంڦदթႚ๕Ljெࡔᆶ31000ටຶᇀदթă
ג极ࣅ 13C MRI (HP 13C MRI) ᅃዖ࿘ۨཞ࿋໎Lj༑֪եཛྷ໗ڟළ໗ݴڦጱׯၟݛ݆ăᆯ LDH ாٝฉۙڦڞ代谢ए
ᇀ Warburg ၳᆌܸሞҵኢዐڦऄႠă
13C-եཛྷ໗MRIᅙࠀׯᆌᆩᇀਆևമଚ၇ҵăኄዖׯၟݛ๕ᆶᆩᇀॠ֪ࣅܔბघ໎ڦ代谢ݒᆌዎଐᇱ݀Ⴀമଚ၇ҵLj
၎Բᇑدཥܠڦ֖ຕ MRI ၎ԲLjᅜሞ߸ራڦ้क़বۅႜዎଐă
ሞړമڦׯۅၟ研৯ዐLj்ኼሞકۇٴHP 13C-եཛྷ໗ MRI ܔገᅎႠCRPCݔڦྷยዃLjࠡỞࢅాሤڦথࣅገ
ᅎLjᅜ༵ࠃ้ํೠࠚୀ代谢ܔࢅዎଐڦ代谢ݒᆌă
极T代谢磁共振全球科研集锦
116
研究结果
结 论
应用方向
࣒ኁ 2DŽ57 Džԥኑྺ CRPCLjᅙገᅎߊሤă࣒ኁኮ
മথࡗܷሗӃࢅᅃዖଣضቛڦ研৯ᄱDŽBET ᅞ
वLjI Džዎଐăਸ਼մܠࢅဇෘࣅڦଐሞए၍ HP 13C ௮
ࢫሀ 1 ߲ሆਸ๔Ljժሞዎଐਸ๔ࢫ 2 ߲ሆႜໜݡăa) ሞࣅ
ଐ 2 ߲ሆ࠵ࢫִڟեཛྷ໗ڟළ໗ገࣅ ୲kPL ٗ 0.026 ইڟگ
0.015 (s-1)ă ጀᅪጀพࢫ 50-60 ௱եཛྷ໗ࢅළ໗ᆶሺेă
ኄీዷᄲᆯᇀઠጲڦڢეࠋ࠶၅ăb) ਸ๔ዎଐࢫ 2
߲ሆڦໜݡ݀၄Ljߵ RECIST ՔጚLjթሲۇٴၭ३ၭDŽ19.3-
11.8 ࡹDžዎଐݒᆌăc) ُྔLjეൣ PSA ٗ 38-13.4 ng/
ml ူইᄺዎଐݒᆌă
ۅ研৯ೠࠚକۅ研৯ೠࠚକܔገᅎႠ࣒ኁႜ HP13C MRI 研৯മଚ၇ҵڟࠡỞࢅాሤገᅎҾ全ႠࢅႜႠLj
ኄ代മଚ၇ҵڦፌံࢅፌዂంڦႚ๕ă ݛ݆ԥॠֱࢅॺ૬ᅏഗยዃLjᄱሰĂၟ֑集ࢅۨଉݴဆăҾ全Ⴀ
ڟڥኤժ࠵ִڟեཛྷ໗ڟළ໗ገࣅ kPL ൔလႠࠡߊࢅገᅎă क़߰݀၄ᅃఁথࢇᆩᄱ࣒ڦኁ kPL ইࣅگଐLjӀቷ
ࡀଣضิׯࢅࣅิၟՔኾă ኄၵ݀၄ԍኤକ HP 13C- եཛྷ໗ MRI ڦᅃօ݀ቛڦҾ全ႠࢅᆶၳႠLjᅜሞ߸
ڦۇٴമቒႠఴႠፇዐڦገᅎႠമଚ၇ҵዐႜศ研৯ă
ገᅎႠඁڸੇႠമଚ၇ҵ
极T代谢磁共振全球科研集锦
117
Prostate Cancer and Prostatic Diseases
https://doi.org/10.1038/s41391-019-0180-z
ARTICLE
Clinical Research
Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux
in prostate cancer metastases to bone and liver: a clinical
feasibility study
Hsin-Yu Chen 1 ●Rahul Aggarwal2 ●Robert A. Bok1 ●Michael A. Ohliger1 ●Zi Zhu1 ●Philip Lee1 ●
Jeremy W. Gordon1 ●Mark van Criekinge1 ●Lucas Carvajal1 ●James B. Slater1 ●Peder E. Z. Larson 1 ●
Eric J. Small2 ●John Kurhanewicz1 ●Daniel B. Vigneron1
Received: 21 August 2019 / Revised: 10 October 2019 / Accepted: 18 October 2019
This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019.
Abstract
Background Hyperpolarized (HP) 13C-pyruvate MRI is a stable-isotope molecular imaging modality that provides real-time
assessment of the rate of metabolism through glycolytic pathways in human prostate cancer. Heretofore this imaging
modality has been successfully utilized in prostate cancer only in localized disease. This pilot clinical study investigated the
feasibility and imaging performance of HP 13C-pyruvate MR metabolic imaging in prostate cancer patients with metastases
to the bone and/or viscera.
Methods Six patients who had metastatic castration-resistant prostate cancer were recruited. Carbon-13 MR examination
were conducted on a clinical 3T MRI following injection of 250 mM hyperpolarized 13C-pyruvate, where pyruvate-to-lactate
conversion rate (kPL) was calculated. Paired metastatic tumor biopsy was performed with histopathological and RNA-seq
analyses.
Results We observed a high rate of glycolytic metabolism in prostate cancer metastases, with a mean kPL value of 0.020 ±
0.006 (s−1) and 0.026 ± 0.000 (s−1) in bone (N = 4) and liver (N = 2) metastases, respectively. Overall, high kPL showed
concordance with biopsy-confirmed high-grade prostate cancer including neuroendocrine differentiation in one case. Interval
decrease of kPL from 0.026 at baseline to 0.015 (s−1
) was observed in a liver metastasis 2 months after the initiation of taxane
plus platinum chemotherapy. RNA-seq found higher levels of the lactate dehydrogenase isoform A (Ldha,15.7 ± 0.7)
expression relative to the dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8 ± 0.9).
Conclusions HP 13C-pyruvate MRI can detect real-time glycolytic metabolism within prostate cancer metastases, and can
measure changes in quantitative kPL values following treatment response at early time points. This first feasibility study
supports future clinical studies of HP 13C-pyruvate MRI in the setting of advanced prostate cancer.
Introduction
Metastatic castration-resistant prostate cancer (mCRPC) is
the most lethal form of the disease, accounting for 31,000
deaths/year in the United States [1]. More than 90% of
patients with mCRPC develop osseous metastases and
nearly half have bone as the only site of the disease [2, 3].
Visceral metastases occur in 10–15% of mCRPC patients
and are associated with high disease burden and poor
prognosis [4, 5]. Despite the emergence of multiple therapies that have been shown to prolong overall survival,
including androgen pathway inhibitors, immunotherapy,
radiopharmaceuticals, and chemotherapeutics, there is an
unmet need for novel therapies to further improve treatment
outcomes [3, 6, 7].
* Daniel B. Vigneron
dan.vigneron@ucsf.edu
1 Department of Radiology and Biomedical Imaging, University of
California, San Francisco, CA, USA
2 Department of Medicine, University of California, San Francisco,
CA, USA
Supplementary information The online version of this article (https://
doi.org/10.1038/s41391-019-0180-z) contains supplementary material,
which is available to authorized users.
1234567890();,:1234567890();,:
极T代谢磁共振全球科研集锦
118
A limitation to the development of novel systemic therapies in mCRPC, especially with bone predominance without
measurable disease by conventional imaging criteria, is the
lack of validated imaging biomarkers to provide real-time
response monitoring. Automated bone indices of radionuclide bone scans have not been sufficiently prospectively
validated, and provide minimal information with respect to
direct tumor metabolic activity. Also, changes in bone scintigraphy with response to therapy can be slow to occur and
are complicated by flare phenomena and differences in
uptake between sclerotic versus lytic lesions [8]. Newer PET
analogs, including agents targeting prostate-specific membrane antigen, have shown promise as a diagnostic tool, but
have limited and conflicting data to support their use to
monitor therapeutic response and resistance [9, 10].
Hyperpolarized 13C MRI (HP 13C MRI) is a stable-isotope
molecular imaging approach that probes pyruvate-to-lactate
metabolism mediated by the upregulation of LDH enzymatic
activity in cancer due to the Warburg effect [11–14] (Fig. 1).
High glycolytic activity and rapid pyruvate-to-lactate conversion are signatures of aggressive cancer [13, 15, 16].
There is also a broad consensus that the pharmacologic
action of chemotherapy is tightly coupled with metabolic
pathways, and responses to chemotherapy might be reflected
as modulations of cancer metabolism [17–19]. Heretofore HP 13C-pyruvate MRI has been successfully utilized in prostate
cancer only in localized disease. This imaging modality has
been used to detect metabolic responses to chemohormonal
therapy in primary prostate cancer [20], at earlier time points
than conventional multiparametric MRI.
In the current pilot imaging study, we aimed to broaden
the scope of HP 13C-pyruvate MRI to the metastatic CRPC
setting, with direct visualization of skeletal and visceral
metastases, in order to provide real-time assessment of
tumor metabolism and metabolic response to therapy.
Methods
Patient selection
Key eligibility criteria included histologic evidence of
prostate cancer, progressive mCRPC by PCWG2 criteria
[7], ECOG performance status of 0 or 1, and adequate end
organ function. All patients underwent restaging CT and
bone scans prior to enrollment, and had at least one identified lesion amenable to HP 13C MRI. Patient recruitment
and HP 13C-pyruvate studies were conducted in compliance
with an IRB-approved protocol (NCT02911467), and all
patients provided written informed consent.
HP 13C patient MRI studies
GMP [1−13C]pyruvic acid (Sigma-Aldrich Isotec, Miamisburg OH) was prepared and loaded in pharmacy kits in
accordance with the IRB- and FDA IND-approved stableisotope manufacturing process. The pyruvic acid was
polarized in a 5T SPINLab (GE Healthcare, Chicago IL)
clinical trial polarizer for 2.5–3 h. Dissolutions yielded
237 ± 10 mM sterile pyruvate with 37.1 ± 3.2% polarization,
0.6 ± 0.4 μM residual radical and 31.0 ± 0.6 °C temperature,
7.5 ± 0.3 pH, 63 ± 4 s dissolution-to-injection time. A
pharmacist oversaw the automatic quality control and
integrity of the sterilization filter, and released the dose
for injection once sterility and safety criteria were met
[21, 22].
All studies were conducted on a clinical 3T MRI
(MR750, GE Healthcare) equipped with multinuclear
spectroscopy capabilities. A custom surface coil with figureeight configuration was applied for both 13C transmit and
receive. A 16-channel abdominal array (GE Healthcare) was
used for proton imaging.
Follow-up 13C-pyruvate MRI was optional after the
initiation of systemic therapy for the treatment of mCRPC.
Data acquisition and analysis
The HP-13C acquisition was conducted using a 2D dynamic
MR spectroscopic imaging pulse sequence with a sliceselective spectral-spatial excitation, followed by phaseencode and echo-planar spectroscopic imaging readout [11].
Pulse sequence parameters were as follows: 130 ms/3.5 ms
TR/TE, 2–3 cm slice thickness, 1.2–1.5 cm in plane spatial
and 3 s temporal resolutions, 60 s acquisition window, 545
Hz bandwidth, constant flip angle through time with pyruvate 10°, and lactate 20°. Scan started 5 s following the
end of the injection. Patients were asked to hold their breath
as long as possible, after which they were instructed to
breathe gently and resume breath holding as tolerated.
Conventional proton T1-weighted spoiled gradient-echo
(TR/TE = 4.3 ms/1.9 ms) images were acquired for anatomic reference. Dynamic HP 13C MRI datasets were processed by applying even–odd lobe phasing, B0-shift
correction, tensor-low-rank signal enhancement [23], spectral baseline correction [24], followed by a phase-sensitive
peak quantification. The pyruvate-to-lactate conversion rate,
Fig. 1 An illustration of LDH-mediated aerobic glycolysis and relevant metabolic pathways
H.-Y. Chen et al.
极T代谢磁共振全球科研集锦
119
kPL, was evaluated using an inputless single-compartment
two-site exchange model [25], and the value reported was
the maximum over ROI of the lesion identified on proton
MRI. Total carbon signal-to-noise ratio (SNR) was reported
as summed SNR of 13C-labeled tracers averaged over time.
The image processing tools are located under—SIVIC
Image Processing/Display: https://sourceforge.net/projects/
sivic, Hyperpolarized MRI Toolbox: https://github.com/La
rsonLab/hyperpolarized-mri-toolbox.
Metastatic tumor biopsy acquisition and analysis
CT-guided metastatic tumor biopsies following HP MRI
acquisition were obtained in five out of the six patients
enrolled in the study (Table 1). Tumor biopsies were
obtained for both fresh frozen processing and formalin fixed
paraffin embedded (FFPE) processing. FFPE tissues were
used for histologic diagnosis, while frozen tissue underwent
Laser Capture Microdissection for RNA-seq profiling as
previously described [6]. Expression levels reported as log
(1 + (TPM × 106
)). Processed RNA-seq data are located in
the Supplementary Materials.
Results
Patient characteristics
Six patients were enrolled in this pilot feasibility study. The
baseline characteristics of the patients are shown in Table 1.
All patients had progressive mCRPC at study entry. Five of
the patients underwent CT-guided metastatic tumor biopsy
of the target lesions following completion of baseline 13Cpyruvate MRI. No adverse events were reported throughout
this study.
HP 13C-pyruvate MRI detects high kPL in bone and
liver metastases
The rate of conversion of pyruvate to lactate (kPL) from
target lesions in each patient is listed in Table 2. There was
high kPL in both bone and liver metastases, with mean kPL of
(0.020 ± 0.006 s−1) and (0.026 ± 0.000 s−1), respectively
[26]. Regions of high kPL were consistent with CT and MRI
radiographic findings of metastatic disease presence, as
shown in the representative kPL image overlays for the target
lesions (Fig. 2a, Supplementary Figs. 1–4).
The liver mass of patient six showed considerable
intratumoral heterogeneity (Supplementary Fig. 4b). Maximum kPL = 0.025 (s−1
) was found in viable tumor, whereas
kPL = 0.004 (s−1
) was observed in a necrotic-appearing
region identified both on CT and the delayed phase of
contrast T1-weighted images.
Table 1 A summary of clinically relevant information from each patientPatient Agea Target metastatic site Gleason scoreb Serum PSA (ng/ml)a Metastatic tumor biopsy pathology Most recent prior systemic therapy
1 75 Left iliac wing 4
+ 5 171.7 Adenocarcinoma
+ Small cell neuroendocrine carcinoma (SCNC) Enzalutamide
+ Investigational agent
2 57 Liver 4 + 4 Baseline: 38 Follow-up: 13.4 High-grade adenocarcinoma Investigational agent3 83 Rib 4 + 4 89.6 No biopsy performed Enzalutamide4 72 Right posterior ilium 4
+ 5 89.2 High-grade adenocarcinoma Docetaxel
+ Ribociclib
5 70 Left posterior ilium 4
+ 5 1482 High-grade adenocarcinoma Docetaxel
6 82 Liver 4 + 3 1439 High-grade adenocarcinoma Docetaxel
+ Carboplatin
aAt study entrybAt initial diagnosis
Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate. . .
极T代谢磁共振全球科研集锦
120
Table 2 also summarizes the total carbon SNR for each
study. The total carbon SNR was 117 ± 126 in bone
metastases (N = 4), and 85 ± 7 between liver involvements
(N = 2). In general, the SNR in all cases was adequate for
reliable kPL fitting (standard error metric σkPL = 0.005 ±
0.003) [27].
In all five patients with paired 13C-pyruvate MRI and
CT-guided biopsy of the target lesions, the histological
evidence of metastatic prostate cancer was detected. In four
of the five cases, the histology demonstrated poorly differentiated adenocarcinoma. In one patient (Patient 1), the
paired metastatic tumor biopsy demonstrated discrete
regions of adenocarcinoma and treatment-emergent small
cell neuroendocrine differentiation (Fig. 2b) [6].
Higher levels of gene expression of the lactate dehydrogenase isoform A (Ldha,15.7 ± 0.7) relative to the
dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8
± 0.9) were detected on RNA-seq of the target metastatic
biopsies (Table 2), consistent with enhanced aerobic glycolysis detected in the rate of conversion of pyruvate to
lactate on HP 13C MRI. No significant difference in Ldha or
Pdha1 expression was observed in the patients imaged in
this study compared with a previously published cohort of
metastases from 200 men with mCRPC (Ldha: 15.1 ± 1.1,
p > 0.17; Pdha1: 12.0 ± 0.9, p > 0.06, Wilcoxon ranked sum
test) [6].
HP 13C MRI detected a metabolic rate decrease in a
metastasis following chemotherapy
Patient 2 had mCRPC with liver metastases and low serum
PSA level. Carboplatin + docetaxel chemotherapy was
started 24 days after the baseline HP 13C MRI study
(Fig. 3c). Follow-up HP MRI study 62 days after the
Table 2 Findings from HP 13C MRI including kPL, and RNA
expression of key genes
Patient kPL of target
lesion (s−1
)
Ldha/Pdha1
expression (in log)
SNR tCarb
1 0.013 15.4/12.3 290.3 ± 248.5
2 Baseline: 0.026
Follow-upa
: 0.015
16.2/13.8 Baseline: 89.7 ± 40.9
Follow-upa: 77.7
3 0.017 Not acquired 131.4 ± 10.2
4 0.026 14.7/11.6 27.4 ± 9.9
5 0.023 16.4/12.6 19.5 ± 3.6
6 0.025 15.6/13.7 88.2 ± 26.1
SNR tcarb: summed SNR of 13C-labeled tracers averaged over time
a
Follow-up was 2 months after initiation of carboplatin + docetaxel
Fig. 2 a Patient 1 (75 years old) was diagnosed with metastatic
castration-resistant prostate cancer with several large osteoblastic
lesions throughout the left hemipelvis and involving left femur. CT
identified a relatively osteolytic lesion in left ilium (Green arrows),
measuring 9.9 × 4.1 cm. The lesion was infiltrative, causing destruction
of the bone cortex and extension into the surrounding soft tissues. T1-
weighted (T1w) spoiled gradient-echo MRI was used to target the same
lesion observed on CT for the HP 13C MR acquisition. Regions of high
pyruvate-to-lactate conversion rate (kPL) correlated with the osseous
lesion on CT and hypointensity on T1w MRI. kPL was estimated 0.013
(s−1
). b The paired bone biopsy demonstrated discrete regions of
adenocarcinoma and treatment-emergent small cell neuroendocrine
differentiation
H.-Y. Chen et al.
极T代谢磁共振全球科研集锦
121
initiation of treatment demonstrated a 42% decrease in
pyruvate-to-lactate conversion rate kPL, from 0.026 to 0.015
s
−1
, in the target liver lesion (Fig. 3a). This was accompanied by interval decrease of the lesion size (Fig. 3b,
19.3–11.8 mm, 39%) based on RECIST 1.1 criteria, along
with serum PSA decline of >50% from baseline (38–13.4
ng/ml), consistent with systemic treatment response.
Discussion
This work reports the results of the first-ever pilot imaging
study of prostate cancer metastases using HP 13C-pyruvate
MRI. This study demonstrates the feasibility of detecting
real-time metabolic activity of metastases and capture
therapeutic response with this emerging stableisotope molecular imaging method. Correlation with
paired metastatic biopsy demonstrated high-grade prostate
adenocarcinoma, including in one case, evidence of neuroendocrine differentiation.
The high pyruvate-to-lactate conversion rate, kPL, via
upregulated LDH activity in cancer, known as Warburg
effect, reflects cancer aggressiveness, and decrease in kPL
can reflect therapeutic response [14, 20]. Overall, the
pyruvate-to-lactate conversion rate kPL found in bone
(0.020 ± 0.006 s−1) and liver (0.026 ± 0.000 s−1) lesions was
either higher than or comparable with that of high-grade
primary prostate cancer (0.013 ± 0.003 s−1
) in a cohort
imaged prior to radical prostatectomy with whole mount
section pathologic correlation [26]. These high kPL values
were correlated with the metastatic biopsy findings of highgrade adenocarcinoma or mixed high-grade adenocarcinoma and small cell neuroendocrine phenotypes in the
patients studied in this report.
Elevated Ldha expression in prostate cancer is known to
be associated with aggressive phenotypes and resistant to
Fig. 3 Patient 2 (57 years old)
was diagnosed with CRPC that
metastasized to liver. The patient
was previously treated with
enzalutamide and an
investigational agent (BET
inhibitor, phase I) with clinical
progression. Chemotherapy of
carboplatin and docetaxel started
~1 month post baseline HP 13C
scan, and follow-up was
2 months after initiation of
therapy. a A decrease in
pyruvate-to-lactate conversion
rate kPL was observed from
0.026 to 0.015 (s−1
) after
2 months of chemotherapy. Note
the increase in pyruvate and
lactate at 50–60 s post injection.
Most likely this is predominately
due to vascular contributions
coming from intestines. b
Follow-up 2 months after
initiation of therapy found a
decrease in lesion size
(19.3–11.8 mm) indicating
therapeutic response based on
RECIST criteria. c In addition,
serum PSA decreased from
38–13.4 ng/ml also indicating
therapeutic response. HA arterial
phase, PV portal venous phase
Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate. . .
极T代谢磁共振全球科研集锦
122
therapy [28–30]. The high Ldha expression relative to
Pdha1 in this study was consistent with a larger published
mCRPC cohort [6], reflective of enhanced aerobic glycolysis, whereas in normal prostate epithelial cells the glucose
metabolism favors oxidative phosphorylation, and Pdha1
expression should predominate (Fig. 1). This suggested that
the metabolic features observed in this study using HP 13Cpyruvate MRI could potentially serve as a representative
cross-section of a much larger patient population with different metastatic sites and types of cell morphology.
A previous study in primary prostate cancer indicated
that kPL reflected early response and resistance to androgen
pathway inhibition [20]. In this communication we
observed a correlation between decreased kPL and clinical
response to the combination of platinum plus taxane chemotherapy in a patient with mCRPC. Although preliminary,
these findings suggest that imaging metabolic signatures
using HP 13C-pyruvate MR could potentially report
responses to a broader range of oncogenic pathway inhibition and drug targets, and may be less susceptible to the
upregulation of membrane protein expression secondary to
ADT [31, 32]. These data suggest that the prospective
evaluation of HP 13C-pyruvate as a response biomarker in
mCRPC patients treated with AR-targeting and cytotoxic
chemotherapy is warranted.
Spatially, regions of high kPL showed good alignment
with radiographic findings of metastases using bone scan,
CT, and proton MRI. Temporally, the time-to-peak of
pyruvate bolus was 29 ± 3 s in pelvic bone cases, 23 s in the
rib case, 34 ± 4 s among the liver cases. The bolus delivery
timing was generally consistent with contrast CT/MRI [33],
and are deemed reasonable in light of hemodynamic variations between subjects, and also the vitals of individual
subject at the time of the scan. The inputless kPL model
applied in this study is relatively immune to variations in
bolus characteristics [25].
Differential kPL was observed between viable and
necrotic-appearing regions of Patient 6’s liver lesion (Supplementary Fig. 4b). These findings are consistent with
other emerging reports of intra- and inter-tumoral heterogeneity in mCRPC [34] and highlight the potential utility of
this imaging tool to clarify tumor biology with real-time
metabolic monitoring [34–37]. The kPL heterogeneity
between metastatic sites/individual patients and its biological underpinning calls for future investigation.
This study also demonstrated that this technology can
provide quantitative metrics of the delivery/uptake of the
injected hyperpolarized carbon isotope by measuring the
total carbon SNR summing the 13C signal observed from
the hyperpolarized pyruvate bolus and downstream metabolic products. Conceptually similar to SUV in PET, total
carbon SNR is a metric of delivery and uptake. Of the
pelvic bone involvements, patient 1, whose lesion appeared
relatively more lytic on CT (Fig. 2a), had higher mean total
SNRPatient 1 = 290 versus the other two cases (SNRPatient 4 =
27.4, SNRPatient 5 = 19.5) with more sclerotic appearances
(Supplementary Figs. 1 and 3). This presents an intriguing
concordance with PET literature in which osteolytic lesions
have shown higher FDG uptake compared with osteoblastic
ones [38–40] and glucose metabolism is known to be differently regulated in sclerotic versus lytic diseases [41].
Several key limitations should be identified for this pilot
study. The correlation between metabolic biomarker kPL and
total carbon SNR is yet to be elucidated in the mCRPC
setting. In addition, the test–retest repeatability data are also
needed moving forward. While the total carbon SNR reports
tracer pharmacokinetics at each metastatic site, its quantitative accuracy can be further enhanced using automatic B1
calibration and correction for QC parameters. This study
utilized a 2D single-slice imaging strategy. Future
advancement in array receiver hardware [42] and MR
acquisition sequences [21, 43] will enable full 3D coverage
of the abdomen/pelvis and seamless integration with
standard-of-care restaging scans. Dissemination of this
technology, in terms of infrastructure and instruments,
requires a clinical 13C polarizer and specialized MRI hardware. The on-site pharmaceutical manufacturing follows the
same standard as PET, allowing for shared facility [14].
These capabilities can readily be instated in high-volume
tertiary centers who manages the majority of the advanced
prostate cancer cohort. Overall, future developments are
warranted to address the technical needs including hardware, image acquisition and quantitative analyses, and the
clinical inquiries deserve to be powered by a larger
cohort study.
These preliminary results highlight the future need to
metabolically characterize lymphadenopathy using HP 13Cpyruvate MRI, as management of nodal disease could be
essential in the realm of biochemically recurrent and oligometastatic PCa [44–47]. For these cohorts of patients,
opportunities for curative treatment are more available, and
clinical outcomes are generally better than those with bone
involvement and thus higher disease burden. Such future
studies could be enabled by the aforementioned technical
advancements to achieve higher resolution and sensitivity,
and new pharmacy QC procedures that reduce HP 13Cpyruvate time-to-injection and thereby improving
SNR [14].
Conclusions
This pilot study evaluated the safety and feasibility to
conduct HP 13C MRI studies of patients with metastatic
prostate cancer to the skeleton and viscera, which represents
the most advanced and lethal form of the disease. Methods
H.-Y. Chen et al.
极T代谢磁共振全球科研集锦
123
were examined and established for instrumentation setup,
pharmacy manufacturing, image acquisition, and quantitative analysis. Safety was demonstrated and highly upregulated pyruvate-to-lactate conversion kPL was observed on
aggressive osseous and hepatic metastases. Interval
decrease of kPL was found for one patient receiving combination chemotherapy, in concordance with conventional
clinical biochemical and imaging biomarkers. These findings warrant further development and investigation of HP
13C-pyruvate MRI in a larger prospective group of men with
metastatic CRPC.
Acknowledgements This work was supported by grants from the NIH
(R01 CA183071, U01EB026412, R01CA215694, R01CA166655,
U01CA232320, and P41EB013598).
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Society AC. Cancer facts and figures 2019. Atlanta, GA: American Cancer Society; 2019.
2. Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F,
Collins DJ, et al. Rationale for modernising imaging in advanced
prostate cancer. Eur Urol Focus. 2017;3:223–39.
3. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS,
Gale J, et al. Survival with newly diagnosed metastatic prostate
cancer in the “Docetaxel Era”: data from 917 patients in the
control arm of the STAMPEDE trial (MRC PR08, CRUK/06/
019). Eur Urol. 2015;67:1028–38.
4. Goodman OB Jr., Flaig TW, Molina A, Mulders PF, Fizazi K,
Suttmann H, et al. Exploratory analysis of the visceral disease
subgroup in a phase III study of abiraterone acetate in metastatic
castration-resistant prostate cancer. Prostate Cancer Prostatic Dis.
2014;17:34–9.
5. Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R,
Bianchini D, et al. Visceral disease in castration-resistant prostate
cancer. Eur Urol. 2014;65:270–3.
6. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas
GV, et al. Clinical and genomic characterization of treatmentemergent small-cell neuroendocrine prostate cancer: a multiinstitutional prospective study. J Clin Oncol. 2018;36:2492–503.
7. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci
MA, et al. Design and end points of clinical trials for patients with
progressive prostate cancer and castrate levels of testosterone:
recommendations of the prostate cancer clinical trials working
group. J Clin Oncol. 2008;26:1148–59.
8. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis:
an update. World J Radiol. 2015;7:202–11.
9. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R,
Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to
androgen receptor inhibition: first human experience. J Nucl Med.
2017;58:81–4.
10. Seitz AK, Rauscher I, Haller B, Krönke M, Luther S, Heck MM,
et al. Preliminary results on response assessment using 68 GaHBED-CC-PSMA PET/CT in patients with metastatic prostate
cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol
Imaging. 2018;45:602–12.
11. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark
AL, Ferrone M, et al. Metabolic imaging of patients with prostate
cancer using hyperpolarized [1-C-13]Pyruvate. Sci Transl Med.
2013;5:198ra108
12. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson
L, Lerche MH, et al. Increase in signal-to-noise ratio of >10,000
times in liquid-state NMR. Proc Natl Acad Sci USA.
2003;100:10158–63.
13. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML,
Zhang VY, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and
grading. Cancer Res. 2008;68:8607–15.
14. Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson
JA, Brindle K, Cunningham CH, et al. Hyperpolarized (13)C
MRI: path to clinical translation in oncology. Neoplasia.
2018;21:1–16.
15. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a
metabolic key player in cancer. Cancer Res. 2011;71:6921–5.
16. Kim JW, Dang CV. Cancer’s molecular sweet tooth and the
Warburg effect. Cancer Res. 2006;66:8927–30.
17. Gonzalez PS, O’Prey J, Cardaci S, Barthet VJA, Sakamaki JI,
Beaumatin F, et al. Mannose impairs tumour growth and enhances
chemotherapy. Nature. 2018;563:719–23.
18. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg
effect in chemosensitivity: targeting lactate dehydrogenase-A resensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
2010;9:33.
19. Timm KN, Kennedy BW, Brindle KM. Imaging tumor metabolism to assess disease progression and treatment response. Clin
Cancer Res. 2016;22:5196–203.
20. Aggarwal R, Vigneron DB, Kurhanewicz J. Hyperpolarized 1-
[(13)C]-pyruvate magnetic resonance imaging detects an early
metabolic response to androgen ablation therapy in prostate cancer. Eur Urol. 2017;72:1028–9.
21. Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van
Criekinge M, et al. Technique development of 3D dynamic CSEPSI for hyperpolarized (13) C pyruvate MR molecular imaging
of human prostate cancer. Magn Reson Med. 2018;80:2062–72.
22. Park I, Larson PEZ, Gordon JW, Carvajal L, Chen HY, Bok R,
et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in
patient studies. Magn Reson Med. 2018;80:864–73.
23. Brender JR, Kishimoto S, Merkle H, Reed G, Hurd RE, Chen AP,
et al. PET by MRI: Glucose Imaging by 13C-MRS without
dynamic nuclear polarization by noise suppression through tensor
decomposition rank reduction. bioRxiv. 2018; preprint 15 February 2018; https://doi.org/10.1101/265793.
Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate. . .
极T代谢磁共振全球科研集锦
124
24. Nelson SJ, Brown TR. The accuracy of quantification from 1d
nmr-spectra using the piqable algorithm. J Magn Reson.
1989;84:95–109.
25. Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M,
et al. Investigation of analysis methods for hyperpolarized 13Cpyruvate metabolic MRI in prostate cancer patients. NMR
Biomed. 2018;31:e3997.
26. Korn N, Larson PEZ, Chen H-Y, Gordon JW, Bok RA, Van
Criekinge M, et al. The rate of hyperpolarized [1-13C] pyruvate to
[1-13C] lactate conversion distinguishes high-grade prostate cancer from low-grade prostate cancer and normal peripheral zone
tissue in patients. Proceedings of the 26th Annual Meeting of
ISMRM, Paris France. 2018; International Society for Magnetic
Resonance in Medicine.
27. Mammoli D, Gordon J, Autry A, Larson PEZ, Li Y, Chen HY,
et al. Kinetic modeling of hyperpolarized carbon-13 pyruvate
metabolism in the human brain. IEEE Trans Med Imaging.
2019; e-pub ahead of print 2 July 2019; https://doi.org/10.1109/
TMI.2019.2926437.
28. Bok R, Lee J, Sriram R, Keshari K, Sukumar S, Daneshmandi S,
et al. The role of lactate metabolism in prostate cancer progression
and metastases revealed by dual-agent hyperpolarized (13)C
MRSI. Cancers. 2019;11:257.
29. Hiew K, Hart CA, Ali A, Elliott T, Ramani V, Sangar V, et al.
Primary mutational landscape linked with pre-docetaxel lactate
dehydrogenase levels predicts docetaxel response in metastatic
castrate-resistant prostate cancer. Eur Urol Focus. 2019;5:
831–41.
30. Koukourakis MI, Giatromanolaki A, Panteliadou M, Pouliliou SE,
Chondrou PS, Mavropoulou S, et al. Lactate dehydrogenase 5
isoenzyme overexpression defines resistance of prostate cancer to
radiotherapy. Br J Cancer. 2014;110:2217–23.
31. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al.
Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol
Oncol. 2018;1:78–82.
32. Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe
SP, Pomper MG, et al. PSMA Ligands for PET imaging of
prostate cancer. J Nucl Med. 2017;58:1545–52.
33. Heiken JP, Bae KT. Contrast medium administration and scan
timing for MDCT. In: Marchal G, Vogl TJ, Heiken JP, Rubin GD
(eds). Multidetector-Row Computed Tomography, Springer: New
York 2005, pp 13–20.
34. Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B,
et al. Assessment of tumor heterogeneity: an emerging imaging
tool for clinical practice? Insights Imaging. 2012;3:573–89.
35. Hockel M, Vaupel P. Tumor hypoxia: definitions and current
clinical, biologic, and molecular aspects. J Natl Cancer Inst.
2001;93:266–76.
36. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald
TY, et al. Molecular characterization of neuroendocrine prostate
cancer and identification of new drug targets. Cancer Discov.
2011;1:487–95.
37. Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H,
Erho N, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence
of prostate cancer: a retrospective cohort study. Lancet Oncol.
2014;15:1521–32.
38. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W,
et al. Detection of bone metastases in patients with prostate cancer
by 18F fluorocholine and 18F fluoride PET-CT: a comparative
study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74.
39. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike
K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic
bone metastases in patients with breast cancer. Eur J Nucl Med
Mol Imaging. 2005;32:1253–8.
40. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I.
Detection of bone metastases in breast cancer by 18FDG PET:
differing metabolic activity in osteoblastic and osteolytic lesions. J
Clin Oncol. 1998;16:3375–9.
41. Todenhofer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting
bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:
838202.
42. Autry AW, Gordon JW, Carvajal L, Mareyam A, Chen HY, Park
I, et al. Comparison between 8‐and 32‐channel phased‐array
receive coils for in vivo hyperpolarized 13C imaging of the human
brain. Magn Reson Med. 2019;82:833–41.
43. Gordon JW, Chen HY, Autry A, Park I, Van Criekinge M,
Mammoli D, et al. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients.
Magn Reson Med. 2019;81:2702–9.
44. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L,
et al. Pelvic/retroperitoneal salvage lymph node dissection for
patients treated with radical prostatectomy with biochemical
recurrence and nodal recurrence detected by [11C]choline positron
emission tomography/computed tomography. Eur Urol.
2011;60:935–43.
45. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De
Bruycker A, et al. Surveillance or metastasis-directed therapy for
oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.
46. Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: reality or figment of imagination? Cancer. 2019;125:
340–52.
47. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T,
et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part II:
treatment of relapsing, metastatic, and castration-resistant prostate
cancer. Eur Urol. 2017;71:630–42.
H.-Y. Chen et al.
极T代谢磁共振全球科研集锦
126
极T代谢磁共振全球科研集锦
127
心血管篇
极T代谢磁共振全球科研集锦
极T代谢磁共振全球科研集锦
128
Hyperpolarized 13C Metabolic MRI of the
Human Heart: Initial Experience
研究背景
研究结论
应用方向
研究结果
研究对象
႐ሤీଉ߀Վሞ႐ປቛዐഐڟዘᄲፕᆩăକٗࠀీցڟ代ۙ฿ڦ႐ປײࡗዐዐक़代谢ᅴڦፕᆩLj研৯
ႎዎଐݛ݆ڦᆶയ૰ࢅထྭڦ০ă༹ా႐ሤ代谢ᅙᆶڦೠݛࠚ݆Ԉઔኟۉጱ݀พ֫ฝᆖDŽPETDžࢅ磁共振հ
DŽMRSDžăMRS ၌ᇀডڦگଳ௺܈Ljॠ֪代谢ڦ૰ీᆶ၌ǗPET ৈీೠࠚ೯༥༛ဦԇײࡗڦLj݆ܔ೯༥
༛ࢫჄ༛টዐڦ代谢ୟ০त代谢ඁၠႜೠࠚLjཞ้ PET ๖ጷव٪ሞᅃۨवଉۉڦޖพLjܔႴᄲዘް๑ᆩڦ
൧ᆶ၌ă
ג极ࣅ] 1-13C]pyruvate ׯ़ၟᆶߛᇀ MRS ຕ߲ຕଉपڦ႑ࡽሺഽLjཞ้ᅜܔ༛টዐक़ׂեཛྷ໗ڦփཞ代谢ඁ
ၠႜॠ֪LjᄺۉޖพڦᆖၚLjႎڦᆶയ૰႐ሤ代谢ׯၟरຍă
ْሞටૌ႐Ԩ研৯ሤฉቛਸג极ࣅ] 1-13C]pyruvate 代谢ׯၟLj༑եཛྷ໗႐ሤ代谢ײࡗዐ代谢ॠ֪ڦႜႠᅜ
त၎ᆌ代谢০٣ࣅாڦऄႠă
ᆶኁۼీڦࡻఱג极ࣅ] 1-13C]pyruvate ׯၟײࡗLjփଆݒᆌăሞᅃْׯၟዐ຺ዖா٣ݒࣅᆌᅜॠ
֪ڦڟǖեཛྷ໗ྃൠா (PDC)Ăեҽ໗ገҽா (ALT)Ăළ໗ྃൠா (LDH) ࢅ༐໗᷿ா (CA)ă႐कా [
13C] ༐໗ൠჸ႑ࡽ
ᇑڞեཛྷ໗ཚࡗ၍૭༹ఈڦ PDC ாऄႠׯԲ૩Ljُ݀၄ీᆶዺᇀएᇀ PDC ऄႠۙবڦ႐ሤ代谢ૌदթዎଐݛ
ӄڦ研৯ăኄLj૧ᆩణമڦ 13C ג极ࣅरຍĂҾ全ĂఱႠଆںࡻೠࠚեཛྷ໗ሞට༹ాڦ代谢ႜڦă
ኟ႐ሤ代谢ऐǗथႠඍე / ም࠺ጀฅࢫ႐कऄ૰ೠࠚǗ႐ປራࢅྟ代谢ՎࣅǗ႐ປ代谢Ӝၠዎଐ研৯Ǘ
༛ౖթ႐कթೠڪࠚă
ኟኾᇼኁ႐ሤ[1-13C]pyruvateLj[
13C]༐໗ൠჸLj[13C]ළ
໗၂ၟă[ 13C]༐໗ൠჸ႑ࡽዷᄲਆ၌ᇀፑ႐कǗ[1-
13C]pyruvate႑ࡽዷᄲሞ႐ሤഹDŽეDžLjփሞ႐क
ዐǗ[
13C]ළ໗ཞ้ሞ႐ࢅ႐कዐᆶă
4ఁॳኾᇼኁǖኟ႐क代谢ऐ
极T代谢磁共振全球科研集锦
129
DOI: 10.1161/CIRCRESAHA.116.309769 1
BRIEF ULTRARAPID COMMUNICATION
Hyperpolarized 13C Metabolic MRI of the Human Heart: Initial Experience
Charles H. Cunningham1,2, Justin Y.C. Lau1,2, Albert P. Chen3, Benjamin J. Geraghty1,2, William J.
Perks4
, Idan Roifman5, Graham A. Wright1,2,5 Kim A. Connelly6
1
Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada; 2Medical Biophysics, University
of Toronto, Toronto, ON, Canada; 3GE Healthcare, Toronto, ON, Canada; 4Pharmacy, Sunnybrook Health
Sciences Centre, Toronto, ON, Canada; 5Schulich Heart Program, Sunnybrook Health Sciences Centre,
Toronto, ON, Canada, and; 6
Cardiology, St. Michael’s Hospital, Toronto, ON, Canada.
Running title: Hyperpolarized MRI of the Human Heart
Subject Terms:
Metabolism
Translational Studies
Magnetic Resonance Imaging (MRI)
Heart Failure
Hypertrophy
Address correspondence to:
Charles H. Cunningham
M7-613
2075 Bayview Ave.
Toronto, ON
M4N 3M5
Canada
Tel: 416-480-5021
Fax: 416-480-5718
chuck@sri.utoronto.ca
In August 2016, the average time from submission to first decision for all original research papers submitted
to Circulation Research was 13.98 days.
极T代谢磁共振全球科研集锦
130
DOI: 10.1161/CIRCRESAHA.116.309769 2
ABSTRACT
Rationale: Altered cardiac energetics is known to play an important role in the progression towards heart
failure. A non-invasive method for imaging metabolic markers that could be used in longitudinal studies
would be useful for understanding therapeutic approaches that target metabolism.
Objective: To demonstrate the first hyperpolarized 13C metabolic magnetic resonance imaging (MRI) of the
human heart.
Methods and Results: Four healthy subjects underwent conventional proton cardiac MRI followed by 13C
imaging and spectroscopic acquisition immediately following intravenous administration of a 0.1 mmol/kg
dose of hyperpolarized [1-13C]pyruvate. All subjects tolerated the procedure well with no adverse effects
reported up to one month post-procedure. The [1-13C]pyruvate signal appeared within the chambers but not
within the muscle. Imaging of the downstream metabolites showed 13C-bicarbonate signal mainly confined
to the left ventricular myocardium whereas the [1-13C]lactate signal appeared both within the chambers and
in the myocardium. The mean 13C image signal-to-noise ratio was 115 for [1-13C]pyruvate, 56 for 13Cbicarbonate, and 53 for [1-13C]lactate.
Conclusions: These results represent the first 13C images of the human heart. The appearance of 13Cbicarbonate signal after administration of hyperpolarized [1-13C]pyruvate was readily detected in this
healthy cohort (N=4). This shows that assessment of pyruvate metabolism in vivo in humans is feasible
using current technology.
ClinicalTrials.gov Identifier: NCT02648009
https://clinicaltrials.gov/ct2/show/NCT02648009?term=hyperpolarized+pyruvate&rank=4
Keywords: metabolism, DNP, hyperpolarized, carbon-13, pyruvate, magnetic resonance imaging,
magnetic resonance spectroscopy, metabolic imaging, heart failure, 13C, mitochondria.
Nonstandard Abbreviations and Acronyms:
CMR cardiac magnetic resonance
DNP dynamic nuclear polarization
PDC pyruvate dehydrogenase complex
RF radiofrequency
极T代谢磁共振全球科研集锦
131
DOI: 10.1161/CIRCRESAHA.116.309769 3
INTRODUCTION
Understanding the role of altered intermediary metabolism in driving the transition from functional
compensation to decompensated heart failure remains a promising avenue for the development of new
therapies [1,2,3,4]. The foundations of cardiac metabolism research are built on experiments in vitro and
in the isolated perfused heart [5,6]. However, to reproduce the effects of insulin and other hormones, plasma
substrate levels, and workload/energy demand, in vivo assessment of cardiac metabolism is of paramount
importance.
Existing clinical imaging modalities for studying cardiac metabolism include positron emission
tomography (PET) and magnetic resonance spectroscopy (MRS). Whilst providing unique insights into
metabolism, both techniques suffer limitations. MRS is only able to detect a limited range of biochemical
reactions due to the inherent low sensitivity of this technique and PET gives no information about the
metabolic fate of the substrate beyond its cellular uptake. Furthermore, PET tracers deliver a dose of
ionizing radiation, thus limiting repeated application. New methods for non-invasively probing the
dynamics of cardiac metabolism in patients are still needed to augment the information currently available
to the clinician.
Hyperpolarized carbon-13 (13C) magnetic resonance imaging (MRI) is promising in this regard,
since it can give images showing the uptake of metabolic substrates and subsequent intracellular conversion
into downstream products [7,8,9,10]. The method relies on rapid dissolution dynamic nuclear polarization
(DNP), which can provide a signal enhancement of more than four orders of magnitude [7]. Measurements
based on these images may give new information about the metabolic state of the heart in individual
patients. In addition to its scientific value as a powerful tool for investigating normal cardiac metabolism
[11], developments in preclinical models support the potential clinical value of 13C MRI in evaluating
pathologies of the human heart including: myocardial viability following acute ischemia/reperfusion injury
[12], early- and late-onset metabolic changes in the failing heart [13], and diabetic cardiomyopathy [14].
Using the substrate [1-13C]pyruvate, which is an important intermediate of cellular metabolism, this
study demonstrates the feasibility of observing, in a single exam, the following four different single-step
enzyme-catalyzed reactions: pyruvate dehydrogenase (PDC), alanine aminotransferase (ALT), lactate
dehydrogenase (LDH), and carbonic anhydrase (CA). Of particular interest is the 13C-bicarbonate signal
that can be measured within the myocardium after an intravenous injection of [1-13C]pyruvate, which is
proportional to flux of pyruvate through PDC on the mitochondrial membrane [8]. Since 13C MRI can be
integrated into a conventional cardiovascular magnetic resonance (CMR) workup with only a small addition
to the scan duration (e.g. 10 minutes), the translation of this new form of MRI to patient studies is readily
achievable, particularly where cardiac MRI is already used clinically. The first images of hyperpolarized 13C MRI in the human heart are presented in this pilot study in four healthy volunteers.
极T代谢磁共振全球科研集锦
132
DOI: 10.1161/CIRCRESAHA.116.309769 4
METHODS
Healthy subjects (N=4) were recruited and gave written informed consent under a protocol approved by the
Sunnybrook Research Ethics Board and approved by Health Canada as a Clinical Trial Application.
Subjects were instructed to eat as they normally would, and an oral carbohydrate load was administered
approximately 1 hour before the pyruvate injection as 35 g of GatoradeTM powder in water, containing 34
g of sucrose and dextrose, to be consistent with a protocol previously established for preclinical cardiac
imaging [15]. A 20 gauge intravenous catheter was placed in the left arm before each subject was positioned
supine and feet first within a 13C volume transmit coil system (GE Healthcare, Cleveland OH) installed on
a GE MR750 3.0 Tesla MRI scanner (GE Healthcare, Waukesha WI). The 13C receiver coil system
consisted of two separate paddles each containing four receiver elements (channels) [16]. One paddle was
positioned on the anterior chest wall over the heart, with the other paddle under the upper left back. The
left arm was fully extended, positioned directly by the side of the subject and supported with padding to
prevent direct contact with the transmit coil. A pulse oximeter was placed on the left index finger for
cardiac triggering.
The investigational product, designated with the generic name “Hyperpolarized (13)C Pyruvate Injection”,
was prepared using a General Electric SPINLabTM system [17] equipped with the Quality Control (QC)
module, which provides automated measurement and display of release parameters. Each dose was
compounded from 1.47 ± 0.05 g of [1-13C]pyruvic acid (Sigma Aldrich, St. Louis MO) combined with
AH111501 [Tris(8-carboxy-2,2,6,6 (tetra(methoxyethyl) benzo-[1,2-4,5ƍ]bis-(1,3)dithiole-4- yl)methyl
sodium salt] (Syncom, Groningen, The Netherlands) in a 49:1 weight by weight ratio, respectively. Once
frozen in the polarizer, each sample was exposed to microwave irradiation for approximately 3 hours to
achieve maximum steady-state polarization. The other components within the sterile fluid pathway were
19.0 ± 0.5 mL of sterile water for injection, which is heated and used to rapidly dissolve the frozen sample,
and a buffered base and chelating solution in the receiver vessel made by mixing 17.5 ± 0.5 mL of a stock
solution (600 mmol/L NaOH, 333 mmol/L Tris base, 333 mg/L disodium EDTA) with 19.0 ± 0.5 mL of
sterile water for injection.
Short-axis cardiac-gated CINE images were acquired from slices covering the left ventricle using the body
coil for both transmit and receive, with a separate breath-hold performed for each slice. After completion
of the anatomical scanning, a pre-scan calibration of the 13C receive frequency and transmit power was
performed using the signal from a 1.5 cm diameter spherical phantom containing an ~8 mol/L solution of 13C-urea, which was fixed on top of the anterior receiver coil housing. The dissolution of the polarized
sample was initiated by the operator, and the QC parameters were evaluated by the study pharmacist to
ensure the parameters were within specifications. Upon release, the dose syringe was rapidly loaded onto
a Spectris Solaris power injector (Medrad, Indianola PA) and the volume corresponding to a 0.1 mmol/kg
dose was injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s.
The 13C imaging data acquisition was initiated at the end of the saline flush, and was preceded by the same
automated breath-hold instructions as used for the anatomical scanning. The data acquisition consisted of
slice-selective spectral-spatial excitation of the 13C-bicarbonate resonance in 6 slices of 1 cm thickness
covering the left ventricle [15]. As a cardiac-gated sequence, the heart rate affects the scan time and sets
an upper limit on the number of slices that can be acquired per heartbeat; the breath-hold duration sets the
lower limit. To maintain a reasonable breath-hold duration, three slices were sequentially excited and
imaged within each cardiac cycle (taking two cardiac cycles to complete all 6), with the cardiac trigger
delay set such that the acquisition window was aligned with diastole. These six slices were then imaged at
the [1-13C]lactate and [1-13C]pyruvate resonances and the whole process was repeated three times, taking
18 cardiac cycles to complete. The nominal spatial resolution was 8.8 mm × 8.8 mm in-plane with a 48 cm
field-of-view.
极T代谢磁共振全球科研集锦
133
DOI: 10.1161/CIRCRESAHA.116.309769 5
Immediately following the 13C imaging, the residual hyperpolarized magnetization was used to acquire MR
spectroscopic data from the whole heart. For the first subject, a slice-selective radiofrequency (RF) pulse
was used (nominal flip angle = 30 degrees, 10 cm axial slab covering the heart) and the acquisition was not
cardiac gated (repetition time of 3 s). For the three subsequent subjects, a 200 µs non-selective RF pulse
was used (nominal flip angle = 18 degrees) and the acquisition was cardiac gated so the repetition times
were approximately 3 s (3 to 4 inter-beat intervals, depending on heart rate). The shorter RF pulse was
intended to excite the 13CO2 resonance, which was not observable in the data from the first subject. Wholeheart spectroscopy was used to provide adequate signal, given that much of the magnetization had likely
been consumed by the preceding 13C imaging.
RESULTS
The four subjects recruited were male with no known prior cardiac history. Their mean age was 41
(range 28 to 48). The mean left ventricular (LV) ejection fraction was 61% (range 55% to 66%). The LV
end diastolic and end systolic volumes indexed to body surface area were 104 (range 82 to 115) and 41
(range 30 to 51) mL/m2
respectively. The mean LV mass (indexed to BSA) was 84 (range 62 to 93) g/m2
(see Table 1).
Of the 4 doses injected, the mean polarization was 28% (range 17% to 35%), pH was 7.35 (range
7.3 to 7.4), temperature was 36.4°C (range 36.0°C to 37.0°C). The duration from dissolution to the start of
imaging ranged from 66 to 71 seconds. Imaging scan duration ranged from 14 to 21 secs. The injected
volume of [1-13C]pyruvate ranged from 29 to 37 mL to achieve 0.1 mmol/kg dose.
All subjects tolerated the procedure well. Two subjects noted a “sweet” taste following [1- 13C]pyruvate injection which dissipated shortly afterwards. No serious adverse effects were noted. During
injection there was no change in heart rate and no reported change in respiration. Non-invasive blood
pressure measured prior to the CMR examination and post [1-13C]pyruvate injection did not vary
significantly. No subject reported any adverse effects up to one month post [1-13C]pyruvate injection. For
subject 04, the 13C imaging acquisition failed due to a scanner malfunction, but the subsequent 13C
spectroscopy acquisition was successful.
Figure 1 shows time-integrated [1-13C]pyruvate, 13C-bicarbonate and [1-13C]lactate images from
two of the three normal healthy volunteers with successful imaging acquisitions. These images were
reconstructed from only the four channels on the anterior chest wall, as the posterior channels gave
insignificant signal. From the spatial distributions observed in the metabolite images, the 13C-bicarbonate
signal appeared mainly confined to the LV myocardium while the [1-13C]pyruvate appeared within the
chambers (in the blood pool) but not within the muscle. In contrast, the [1-13C]lactate signal appeared both
within the chambers and in the myocardium.
The maximum image signal-to-noise ratio (SNR) for each 13C-labelled metabolite across the
subjects is plotted in Figure 2. This was calculated as the maximum pixel value for the corresponding
metabolite image divided by the standard deviation of the noise in the image background, and serves as a
benchmark for the image SNR that can be obtained in humans for this particular spatial resolution and at
the polarization achievable currently. However, since the SNR in MRI varies linearly with the voxel
volume (holding other parameters equal) this benchmark will be useful for the design of future experiments
in patients. The modest spatial resolution used here (8.8 × 8.8 mm in-plane, 10 mm through plane) resulted
in readily detectable metabolic conversion within the tissue and enabled observations about the spatial
distribution of the substrate and products. The bicarbonate signal-to-noise in the right ventricular
极T代谢磁共振全球科研集锦
134
DOI: 10.1161/CIRCRESAHA.116.309769 6
myocardium was insufficient for reliable assessment with the chosen spatial resolution and coil
configuration.
Representative dynamic 13C spectra from one of the subjects are shown in Figure 3. Despite starting
the spectroscopic acquisition following the completion of 13C imaging (and at least 90 s after dissolution)
major metabolites from [1-13C]pyruvate were all observed in the spectra (Figure 3a,b). The peaks observed
correspond to [1-13C]lactate (185 ppm), [1-13C] alanine (179 ppm), [1-13C]pyruvate (172 ppm), and 13Cbicarbonate (162 ppm). From one of the data sets using the non-selective RF pulse, 13CO2 was also observed
and the pH calculated from the 13C-bicarbonate and 13CO2 signals using the Henderson-Hasselbalch
equation was 7.1. For three subjects with cardiac-gated spectroscopic acquisitions, the bicarbonate-topyruvate ratios remained relatively stable during the time points with sufficient SNR for quantification,
ranging from 20 to 70 seconds. In contrast, the lactate-to-pyruvate ratio increased over a similar time frame
for all subjects (Figure 3c-d).
DISCUSSION
To the best of the authors’ knowledge, these results represent the first hyperpolarized 13C images
of the human heart. [1-13C]pyruvate metabolism in the LV myocardium, as indicated by the generation of
the 13C-bicarbonate signal was readily detected in this healthy cohort. This suggests that that this
technology may one day allow a direct measure of flux through the pyruvate dehydrogenase complex in the
myocardium in vivo in humans. The opposing patterns observed in Figure 1 for the [1-13C]pyruvate
substrate and the 13C-bicarbonate product are consistent with rapid [1-13C]pyruvate flux through the LV
myocardial PDC (consuming the [1-13C]pyruvate in the muscle). The diffuse appearance of the [1- 13C]lactate signal was consistent with previous data from a porcine model, where the [1-13C]lactate signal
appeared diffuse in both the blood and the tissue prior to ischemia [12]. Understanding the more diffuse
appearance of the [1-13C]lactate signal would require further experiments, but it is clear that the largest
component is in the blood pool (at the time points imaged here) and that any interpretation of whole-heart 13C spectra must take this into account.
Rationalization of the temporal evolution of the lactate-to-pyruvate and bicarbonate-to-pyruvate
ratios observed in Fig. 3(c) and 3(d) requires some degree of speculation. These data were acquired
approximately one minute after the initial bolus, so the spatial distribution of metabolites seen in Figure 1
had likely changed. A steady state was not observed for the lactate-to-pyruvate ratio, perhaps as a result of
LDH mediated label exchange between the 13C-enriched pyruvate pool and the larger pre-existing lactate
pool [18], resulting in the [1-13C]lactate to [1-13C]pyruvate ratio continuing to approach the endogenous
lactate to pyruvate ratio. Unlike the reversible label exchange between pyruvate and lactate, the labeling
of 13C-bicarbonate is the result of an irreversible forward flux, resulting in enrichment of 13CO2 and 13Cbicarbonate. Through the normal physiology of aerobic respiration, intracellular 13CO2 is continually
exported and transported away via the blood, draining the 13C-bicarbonate pool. This “negative feedback”
on the 13C-bicarbonate pool may account for the more stable trend in the 13C-bicarbonate to [1-13C]pyruvate
ratio over this timeframe.
Importantly, no adverse events were recorded (except for the taste experienced by two subjects)
and the injection and 13C imaging were well tolerated. With this tool to assess in vivo PDC flux in a rapid,
safe and well tolerated manner, longitudinal studies in humans incorporating this metabolic assessment of
the heart become feasible. The metabolic information comes along with the detailed assessment of cardiac
structure and function from the conventional CMR assessment done during the same scanning session. This
augmented form of CMR is anticipated to provide novel insights into how metabolic changes relate to the
process of functional decompensation leading to heart failure.
极T代谢磁共振全球科研集锦
135
DOI: 10.1161/CIRCRESAHA.116.309769 7
There are several limitations to the current technique and to this study. To apply this method,
specialised equipment in the form of the SPINLabTM and 13C cardiac coils are required, limiting the number
of sites that are currently able to do these studies. With the current polarization level and imaging method,
spatial resolution was limited due to a trade-off with SNR (these will certainly improve in the future as
polarization levels increase and coils are improved). Thus imaging the ischemic heart to assess myocardial
viability, or other structures in the heart, such as the right ventricle, remain technically challenging. Lastly,
this study only included normal volunteers, so the feasibility in a population with disease remains to be
shown.
The clinical potential for this technique remains considerable. As demonstrated by our previous
work in porcine models of heart failure [12], as well as work by other groups [19], the ability to perform
repeated assessments of PDC flux will provide important insights into disease pathogenesis that can
potentially facilitate treatment strategies in the form of PDC modulators. A significant body of work
implicates PDC activity as an important determinant of cardiac function, particularly in states where insulin
resistance occurs [20]. For instance, in insulin-resistant ob/ob mice, enhanced fatty acid metabolism at the
expense of glucose oxidation is associated with impaired contractile function [21]. Indeed, there is a
growing body of evidence to suggest that improving contractile function may be associated with the
normalization of PDC flux. Changes in PDC activity may not only be a marker for abnormal cellular
metabolism and increased oxidative stress, it may serve as a therapeutic target to prevent the development
of heart failure in states where PDC activity is impaired [22]. However, since the relative utilization of fatty
acids and carbohydrates shifts depending on the etiology and stage of disease [23], the appropriate therapy
will require individualization for the particular patient, and this is where CMR plus 13C MRI may be
clinically valuable.
Conclusions.
These results represent the first 13C images of the human heart. The appearance of hyperpolarized
signals of both 13CO2 and 13C-bicarbonate from [1-13C]pyruvate suggests that that this technology may one
day allow a direct measure of flux through the pyruvate dehydrogenase complex in the myocardium in vivo
in humans.
ACKNOWLEDGEMENTS
The authors are grateful to Tracey Rideout, Sergio DeFigueiredo and Stephanie Vidotto for pharmacy
technician support for this study, to Julie Green for coordinating the study, and to Ruby Endre and Garry
Detzler for MR technician support.
SOURCES OF FUNDING
Heart and Stroke Foundation of Canada. Dr KA Connelly is supported by a CIHR New Investigator award.
DISCLOSURES
AP Chen is an employee of GE Healthcare.
极T代谢磁共振全球科研集锦
136
DOI: 10.1161/CIRCRESAHA.116.309769 8
REFERENCES
[1] Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic
interventions. Heart Fail Rev. 2002;7:115-130.
[2] Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation.
2007;116:434-448.
[3] Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, Maggioni A, Fonarow GC, Abel
ED, Campia U, Gheorghiade M. Targeting myocardial substrate metabolism in heart failure: potential for
new therapies. Eur J Heart Fail. 2012;14:120-129.
[4] Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure implications beyond ATP
production. Circ Res. 2013;113:709-724.
[5] Garlick PB, Radda GK, Seeley PJ, Chance B. Phosphorus NMR studies on perfused heart. Biochem
Bioph Res Co. 1977;74:1256-1262.
[6] Bailey IA, Gadian DG, Matthews PM, Radda GK, Seeley PJ. Studies of metabolism in the isolated,
perfused rat heart using 13C NMR. FEBS Lett. 1981;123:315-318.
[7] Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning
M, Golman K. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci
USA. 2003;100:10158–10163.
[8] Merritt ME, Harrison C, Storey C, Jeffrey FM, Sherry AD, Malloy CR. Hyperpolarized 13C allows a
direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci USA.
2007;104:19773–19777.
[9] Golman K, Petersson JS, Magnusson P, Johansson E, Åkeson P, Chai CM, Hansson G, Månsson S.
Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn Reson Med.
2008;59:1005–1013.
[10] Schroeder MA, Cochlin LE, Heather LC, Clarke K., Radda GK, Tyler DJ. In vivo assessment of
pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc Natl
Acad Sci USA. 2008;105:12051–12056.
[11] Schroeder MA, Clarke K, Neubauer S, Tyler DJ. Hyperpolarized magnetic resonance A novel
technique for the In vivo assessment of cardiovascular disease. Circulation. 2011;124:1580-1594.
[12] Lau AZ, Chen AP, Barry J, Graham JJ, Dominguez-Viqueira W, Ghugre NR, Wright GA, Cunningham
CH. Reproducibility Study for Free-Breathing Measurements of Metabolism Using Hyperpolarized 13C in
the Heart. Magn Reson Med. 2013;69:1063-1071.
[13] Schroeder MA, Lau AZ, Chen AP, Gu Y, Nagendran J, Barry J, Hu X, Dyck JR, Tyler DJ, Clarke K,
Connelly KA, Wright GA, CH Cunningham. Hyperpolarized 13C magnetic resonance reveals early‐ and
late‐onset changes to in vivo pyruvate metabolism in the failing heart. Eur J Heart Fail. 2013;15:130-140.
[14] Le Page LM, Rider OJ, Lewis AJ, Ball V, Clarke K, Johansson E, Carr CA, Heather LC, Tyler DJ.
Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C
hyperpolarized magnetic resonance and echocardiography study. Diabetes. 2015;64:2735-2743.
极T代谢磁共振全球科研集锦
137
DOI: 10.1161/CIRCRESAHA.116.309769 9
[15] Lau AZ, Chen AP, Ghugre NR, Ramanan V, Lam WW, Connelly KA, Wright GA, Cunningham CH.
Rapid multislice imaging of hyperpolarized 13C pyruvate and bicarbonate in the heart. Magn Reson Med.
2010;64:1323-1331.
[16] Tropp J, Calderon P, Carvajal L, Robb F, Larson PEZ, Shin P, Vigneron DB, Nelson SJ. A carbon
receive array of 8 elements, interoperable with proton scanning, for human temporal lobe. Proceedings of
the 20th Annual Meeting of ISMRM; Melbourne, Australia. 2012. Abstract 2658.
[17] Ardenkjaer‐Larsen JH, Leach AM, Clarke N, Urbahn J, Anderson D, Skloss TW. Dynamic nuclear
polarization polarizer for sterile use intent. NMR Biomed. 2011;24:927-932.
[18] Witney TH, Kettunen MI, Brindle KM. Kinetic modeling of hyperpolarized 13C label exchange
between pyruvate and lactate in tumor cells. J Biol Chem. 2011;286:24572-24580.
[19] Rider OJ, Tyler DJ. Clinical implications of cardiac hyperpolarized magnetic resonance imaging. J
Cardiov Magn Reson. 2013;15:93.
[20] Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I
General concepts. Circulation. 2002;105:1727-33.
[21] Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED.
Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts.
Diabetes. 2004;53:2366-74.
[22] Lewis AJ, Neubauer S, Tyler DJ, Rider OJ. Pyruvate dehydrogenase as a therapeutic target for obesity
cardiomyopathy. Expert Opin Ther Tar. 2016;20:755-66.
[23] Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, Maggioni A, Fonarow GC, Abel
ED, Campia U, Gheorghiade M. Targeting myocardial substrate metabolism in heart failure: potential for
new therapies. Eur J Heart Fail. 2012;14:120-129.
极T代谢磁共振全球科研集锦
138
DOI: 10.1161/CIRCRESAHA.116.309769 10
FIGURE LEGENDS
Figure 1: Representative 13C images displayed as color overlays on top of grayscale anatomical images in
a mid-left ventricle (LV) slice from subject 01 (a-c) and subject 03 (d-f). The [1-13C]pyruvate substrate was
seen mainly in the blood pool within the cardiac chambers (a,d). Flux of pyruvate through the pyruvate
dehydrogenase complex is reflected in the 13C-bicarbonate images (b,e), with signal predominantly in the
wall of the LV. The [1-13C]lactate signal (c,f) appeared with a diffuse distribution covering the muscle and
chambers.
Figure 2: Grayscale anatomical (a) and 13C images (b-d) from subject 01 are shown separately with the
calculated maximum signal-to-noise ratio (SNR). A summary of maximum image SNR across the different
subjects is shown on the right (e)..
Figure 3. Representative dynamic 13C spectra acquired using a non-selective excitation pulse from one of
the subjects are shown in a) and b). The spectrum in b) is the sum of the 5 consecutive time points shown
in a). Lactate and bicarbonate to pyruvate ratios from the spectroscopic data are shown in c) and d),
respectively. For the three subjects with cardiac-gated spectroscopic acquisitions, the lactate-to-pyruvate
ratios increased over time whereas the bicarbonate-to-pyruvate ratios remained relatively stable during the
time before the signal-to-noise ratio became too low for quantification.
极T代谢磁共振全球科研集锦
139
DOI: 10.1161/CIRCRESAHA.116.309769 11
Novelty and Significance
What Is Known?
● Altered metabolism plays a role in heart failure progression.
● Therapy that targets metabolism will require individualization for the particular patient.
● Hyperpolarized 13C MRI holds the potential to provide a non-invasive metabolic assessment
What New Information Does This Article Contribute?
● The first hyperpolarized 13C images of the human heart.
● Demonstrated the feasibility of an integrated structural/functional/metabolic MRI assessment.
● A hyperpolarized 13C image-quality benchmark in the human heart using current technology
Altered cardiac metabolism has long been known to play a role in progression of heart failure. Although
there are many methods for making in vivo measurements related to metabolism, a non-invasive test that
can be applied longitudinally in patients has remained an unmet need. In this study, an augmented form of
MRI which enables imaging of the metabolic conversion of pyruvate, an important metabolic intermediate,
into its downstream metabolic products is demonstrated for the first time in humans. These results represent
the first 13C metabolic images of the human heart, and open the door to future studies in patients.
极T代谢磁共振全球科研集锦
140
DOI: 10.1161/CIRCRESAHA.116.309769 12
TABLES
Table 1: Subject characteristics and scan details.
Subject ID 01 02 03 04 Mean
Age (yrs) 28 47 48 41 41
Ejection Fraction (%) 64 66 58 55 61
Body surface area (BSA) 1.79 1.95 2.12 1.95 1.95
Left ventricular (LV) mass (g/m2) 62 93 89 92 84
LV end-diastolic volume index (mL/m2) 82 107 110 115 104
LV end-systolic volume index (mL/m2) 30 36 46 51 41
LV stroke volume index (mL/m2) 52 70 64 64 63
Heart rate (beats per minute) 69 57 55 47 57
Dose given (mL) 29.3 33.0 37.0 33.0 33.1
Start of injection from dissolution (s) 66 71 66 66 67
Start of scan from dissolution (s) 77 84 95 82 85
Duration of imaging scan (s) 14 17 19 21 18
Start of spectroscopy from dissolution (s) 100 123 139 132 124
极T代谢磁共振全球科研集锦
141
a b c
10
30
20
20
60
40
5
25
15
80
40
10
50
30
20
60
40
d e f
5 cm 5 cm 5 cm
5 cm 5 cm 5 cm
Pyruvate Bicarbonate Lactate
Pyruvate Bicarbonate Lactate
FIGURE 1
极T代谢磁共振全球科研集锦
142
Bicarbonate Lactate Pyruvate
0
80
160
Maximum Image SNR
5
15
25
10
20
30
20
40
60
Pyruvate
Bicarbonate
Lactate
CINE
40
80
120
5 cm
5 cm
5 cm
5 cm
a
d
b
c
Max SNR = 80
Max SNR = 38 Max SNR = 104
e)
FIGURE 2
极T代谢磁共振全球科研集锦
143
13C bicarbonate
[1-13C] pyruvate
13CO2
[1-13C] lactate
[1-13C] alanine
0
1.0
2.0
3.0
4.0
5.0
20 30 40 50 60 70 80
subject 2
subject 3
subject 4
0
0.2
20 30 40 50 60 70 80
subject 2
subject 3
subject 4
bicarbonate / pyruvate ratio
a) lactate / pyruvate ratio
b)
c)
d)
139 s
Time postinjection
142 s
146 s
149 s
152 s
0.1
0.3
Time from end of imaging (s)
Time from end of imaging (s)
FIGURE 3
极T代谢磁共振全球科研集锦
144
Efect of Doxorubicin on Myocardial
Bicarbonate Production from Pyruvate
Dehydrogenase in Women with Breast Cancer
研究背景
研究结论
应用方向
研究结果
研究对象
ሞথᕾ࣍ૌᄱዎଐڦළ၇ҵ࣒ኁዐLjࡗג 5% ࣒ڦኁ၄႐ሤ۾Ⴀă႐ሤฅऐชփྜ全ൣؤLjڍ၍૭༹
ฅీᇱᅺኮᅃăራ݀၄ᕾ࣍ૌᄱᆅഐڦ႐कฅܔᇀଣݥضዘᄲLjڍణമժ࿄ڦࡻᆖၟă
Ԩ研৯ॽג极ࣅ] 1-13C]pyruvate ׯၟᆌᆩᇀҮி໎ႎޤዺࣅଐമࢫළ၇ҵ࣒ኁڦ႐ሤ代谢ׯၟLj༑৯ܔዎଐമࢫ代
谢ՎࣅೠڦࠚႜႠă
ᆶ࣒ኁۼీںࡻఱג极ࣅ]1-13C]pyruvateׯၟLjփଆᆖၚLjዎଐമए၍13C MRI၎ຼă4߲ଐײኮڦࢫ]
13C]
༐໗ൠჸ႑ࡽԲኵᆶ၂ዸইگLj[
13C] ළ໗႑ࡽᆶူই൵ă7 ߲ڦଐࢫዘް၂ၟକג极ࣅ] 1-13C]pyruvate
ׯၟଆڦࡻዘްႠă
ጺઠLjג极ࣅ] 1-13C]pyruvate ׯၟܔළ၇ҵ࣒ኁࣅଐࢫ႐ሤ۾Ⴀၳᆌڦ代谢ॠ֪௺ڦߌLjዘްࢅڦఱଆ
ăڦࡻ
ࣅଐ႐ሤ۾Ⴀᆅഐ႐कฅራೠࠚǗࣅଐᆅഐڦ႐ሤ۾Ⴀऐ研৯ă
ג极ࣅ]1-13C]pyruvateׯۨၟ࿋DŽADžĂ13C MRS
DŽBDžतҮி໎ዎଐമࢫ代谢ׂۨଉă[
13C]
༐໗ൠჸ၎Բᇀጺ13C႑ࡽԲኵሞዎଐമࢫᆶ၂
ዸইگă
10ఁႴҮி໎ᄱዎଐڦළ၇ҵ࣒ኁǖࣅଐമ
ၟׯ႐ሤ代谢ࢫ